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ABSTRACT
ELUCIDATING THE ROLE OF THE AFRICAN-CENTRIC P47S VARIANT OF TP53 IN
METABOLISM AND FERROPTOSIS
Keerthana Gnanapradeepan
Maureen E. Murphy

The tumor suppressor gene TP53 is the most frequently mutated gene in cancer and
plays a key role in mediating several processes that are critical for preventing tumor formation
and progression. Known as the guardian of the genome, p53 regulates hundreds of genes
involved in various pathways such as apoptosis, cell cycle arrest and senescence. In recent
years, the role of p53 in metabolism, redox state and ferroptosis has begun to emerge. Our lab
has identified an African-specific polymorphic variant of p53 that encodes a serine residue
instead of a proline at amino acid 47 (hereafter S47) and predisposes carriers to cancer. The S47
variant is impaired for tumor suppression and ferroptosis, and S47 cells have an altered redox
state. We sought to use the tumor prone S47 model as a tool to better understand the role of p53
in tumor suppression. Our results demonstrate that mice carrying the S47 variant have greater
metabolic efficiency compared to those with WT p53, along with increased mTOR activity. This
difference in mTOR stems from an impaired protein-protein interaction that occurs in S47,
ultimately due to a difference in cellular redox state. We next identified PLTP as a p53 target
gene that shows decreased transactivation in the S47 variant and mediates ferroptosis resistance
by enhancing lipid storage in HepG2 cells. Taken together, this work sheds light on the emerging
roles p53 plays in tumor suppression, metabolism and ferroptosis. It also provides a better
understanding of an ethnic genetic variant of p53. We expect this work will enable better
personalized medicine approaches and therapeutic options for people who carry this variant.
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Chapter 1: Introduction
This chapter contains excerpts from the following manuscript:
Gnanapradeepan K, Basu S, Barnoud T, Budina-Kolomets A, Kung CP, Murphy
ME. The p53 tumor suppressor in the control of metabolism and ferroptosis.
Frontiers in Endocrinology (2018); 9:124.

1.1 p53: Guardian of the Genome
1.1.1 The role of p53 in cancer
Cancer is most simply described as a disease of uncontrolled cell growth,
resulting from genetic mutations. Hundreds of genes have been identified as playing a
role in tumorigenesis, but among the most notable genes in cancer is TP53, mutated in
more than 50% of human tumors (Leroy et al., 2014). Since first being discovered in
1979, there have been more than 80,000 somatic and germline mutations that have
been observed in this single gene (http://p53.fr). Many factors determine the prevalence
of p53 mutations, such as cancer type and the stage of the tumor. For example, TP53
mutations are found in 80% of small-cell lung cancer and 90% of ovarian cancer, while
there are less than 5% observed in cervical cancer and 10% in leukemia. Exogenous
influences such as viral infection and geographic distribution, in other words how
environmental conditions affect carriers from different areas of the world, are also factors
that can affect the frequency of TP53 mutations (Leroy et al., 2014).
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In many tumor suppressor genes, such as the Retinoblastoma susceptibility gene
RB1, it has been observed that mutations inactivating the tumor suppressive function are
due to loss of the wild-type form of the protein. Interestingly, most cancer-causing TP53
mutations still express a version of the p53 protein. Mutants of p53 generally possess a
single amino acid change that has a profound impact on the function of the protein
(Vousden and Lane, 2007). The most well studied mutations in TP53 occur in the DNA
binding domain of the protein. Mutations in this region impair the ability of p53 to bind to
its target genes and result in the accumulation of mutant p53 (Soussi and Lozano,
2005). Mouse models expressing mutant p53 develop more aggressive cancers and
increased metastasis compared to mice lacking p53 all together (Lang et al., 2004; Olive
et al., 2004).
Most patients carry somatic mutations of p53, in which mutations spontaneously
arise in a certain subset of cells. Germline transmission of p53 mutations has been
characterized as Li-Fraumeni syndrome. Individuals with this disease are born with a
wild-type and mutant from of p53 in all tissues, and exhibit an extremely high incidence
of cancer (Vousden and Lane, 2007). Li-Fraumeni patients have an estimated cancer
risk of 90% by the age of 60, highlighting the devastating impacts of TP53 mutations
(Malkin et al., 1990).

1.1.2 The story of p53: A brief history
In 1979, several research groups independently discovered p53 while studying
the small DNA tumor virus, SV40. These groups reported that when SV40 large tumor
antigen was immunoprecipitated from either SV40 induced tumors or SV40 transformed
2

cells, a non-viral protein with a molecular mass of roughly 53 kilodaltons was also pulled
down with it (Lane and Crawford, 1979; Linzer and Levine, 1979). Shortly after, it was
revealed that this same protein was produced at high levels in tumors whereas very low
levels were found in normal tissue (Rotter, 1983). This corroborated earlier findings that
this protein is abundant in transformed cells and cancer cells, but not in non-transformed
cells (DeLeo et al., 1979). By the mid 1980s, it was widely believed that p53 functioned
as an oncogene, as p53 expression appeared to correlate with enhanced tumorigenesis
(Levine and Oren, 2009).
As more groups began publishing on this protein, each group derived their own
name resulting in confusion in this rapidly growing field. In 1983 at the first International
p53 Workshop in Oxted, UK, several researchers in the field came together and
collectively agreed upon the name ‘p53’, as this protein appears at a molecular weight of
53 kDa when run on an SDS-polyacrylamide gel. Interestingly, it was later found that the
predicted molecular mass is around 43.7 kDa and the overestimation in size is due to
the fact that the proline-rich region hinders the migration of the protein. By then, p53 had
become the standard nomenclature in the field thus this name for the protein remains
today (Levine and Oren, 2009).
As research and technology progressed, many groups began to recognize the
discrepancies with the theory that p53 functioned as an oncogene. Varda Rotter’s group
discovered that the coding sequences for TP53 were essentially deleted in the cell line
HL60, derived from human leukemia (Wolf and Rotter, 1985). Meanwhile the Vogelstein
group found that human colorectal tumors did not contain WT p53, and that the TP53
allele was subject to mutations and/or deletions (Vogelstein et al., 1989). Finlay and
Hinds began studying a clone of p53 that could not recapitulate the transforming
3

phenotype observed with other clones. They began investigating the DNA sequences of
p53 clones they had used in the past, as well as clones obtained from other groups. It
was discovered that each clone carried a unique sequence, suggesting it was very likely
that almost all the clones studied until then carried p53 mutations (Finlay et al., 1988).
This was further validated by comparing the sequence of wild type (WT) Trp53 taken
from normal mouse tissue to the Trp53 sequence taken from mouse tumor tissue. It was
found that the mouse tumor tissue did, in fact, contain mutations of p53 and that these
mutants were capable of inducing cell transformation whereas the WT p53 did not
(Halevy et al., 1991). When WT p53 was overexpressed in the presence of oncogenes
such as MYC and HRAS, transformation was suppressed thus validating the tumor
suppressive function of p53 (Eliyahu et al., 1989; Finlay et al., 1989).
In order for a gene to be considered a tumor suppressor gene, it typically should
meet at least two criteria: 1) humans who harbor germline mutations of this gene should
show increased risk of cancer and 2) animal models who lose this gene should display a
cancer-prone phenotype (Levine and Oren, 2009). TP53 meets both these criteria, as
germline TP53 mutations in humans cause Li-Fraumeni syndrome which results in earlyonset cancer, and p53 null mice were found to be extremely cancer prone (Donehower
et al., 1992; Malkin et al., 1990; Srivastava et al., 1990). All these data, in addition to
many other studies, indicated that TP53 is a tumor suppressor gene and not an
oncogene as originally thought.
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1.2 The structure and function of p53
1.2.1 The Structure of p53
The structure of p53 is composed of two transactivation domains located on the
intrinsically disordered N-terminal region, adjacent to a conserved proline-rich domain,
then followed by the central DNA binding domain (Figure 1.1). The C-terminal region of
the protein encodes its nuclear localization signals, and contains the oligomerization
domain required for p53 transcriptional activity (Kastenhuber and Lowe, 2017). p53
typically exists as a homotetramer (a dimer of dimers), composed of four subunits each
containing 393 amino acids. Under normal conditions, p53 is expressed at low levels.
Each subunit alone has low thermodynamic stability and will rapidly unfold at body
temperature. However, upon stress such as DNA damage, p53 is stabilized by post
translational

modifications.

The

primary

dimers

are

stabilized

by

antiparallel

intermolecular β-sheet and helix packing interactions. The two dimers come together via
a hydrophobic helix and interact to form a tightly packed tetramer that now has high
thermodynamic stability (Canadillas et al., 2006; Cho et al., 1994). The modular structure
of p53 along with the regions of intrinsic disorder enable p53 to adopt various
conformations, allowing it to interact with a number of other proteins.
In order to bind to DNA, a specific response element is required that is generally
composed of two 10 basepair motifs separated by a spacer. The spacer can range from
0-13 basepairs but is typically 0-1 basepairs in most p53 response elements. Different
spacer lengths can pose various conformational restraints and generally, increasing
spacer length decreases the binding affinity of p53. For example, a 5 basepair spacer
would result in two p53 dimers on opposite faces of DNA, whereas a 10 basepair spacer
would result in two dimers on the same face of DNA, requiring significant bending of
5

DNA to enable this interaction (Joerger and Fersht, 2016). TP53 mutations are generally
categorized as contact mutants or conformation mutants, and the majority of tumor
causing TP53 mutations occur in the DNA binding domain. Contact mutants impede p53
from binding to DNA, such as the R273H and R245W mutants, resulting in loss of
transactivation of target genes. Conformation mutants disrupt the physical structure of
p53, such as V143A and R175H mutants (Raj and Attardi, 2017).

1.2.2 Transactivation Domains of p53
Two transactivation domains (TADs) are located on the N-terminus of p53 and
are essential for protein-protein interactions that regulate p53 stability. For example, the
histone acetyltransferase p300, or its paralog CBP, binds in this region and promotes
stabilization of p53 through the acetylation of lysine residues on the C-terminal region of
the protein. This also results in acetylation of nearby histones, enabling chromatin
unwinding and transcription of target genes (Miller Jenkins et al., 2015). Various proteins
bind to this region, such as TFIIH, which is a key component in transcriptional
machinery, or RPA, a protein that plays an important role in DNA replication. Proteins
involved in p53 regulation also bind to this region, such as MDM2 and MDMX, which
both work to inhibit p53 function (Raj and Attardi, 2017).
Under basal conditions, the TAD1/2 domains are intrinsically disordered regions
that adopt a helical conformation when bound to another protein. This disordered
structure in the unbound state allows p53 to adapt easily, bind to a broad range of
proteins and allows for post translational modifications (Miller Jenkins et al., 2015). The
transactivation domains are composed of several acidic amino acids that are
interspersed with bulky hydrophobic residues, which are key to promote binding to other
6

proteins. There are also several serines and threonines in the TAD region, which serve
as targets of phosphorylation and further affect interactions with binding partners (Raj
and Attardi, 2017). For example, phosphorylation of threonine 18 prevents MDM2 from
binding to TAD1 of p53, while enhancing the affinity for many domains of CBP/p300 (Lee
et al., 2010; Teufel et al., 2009). Phosphorylation at serine 46 and threonine 55 enables
subunits of TFIIH to bind (Di Lello et al., 2006). These examples highlight how
modification of the transactivation domains via phosphorylation can modulate p53
function in response to stress (Joerger and Fersht, 2016).
The two transactivation domains (TAD) are both necessary for full p53-mediated
tumor suppression and target gene transactivation, however there are differences with
regards to how certain mutations in each TAD affects gene expression (Hafner et al.,
2019). Brady et al. demonstrated that creating a knock-in mouse with a mutation in the
TAD1 domain (L25Q, W26S) severely impairs transactivation of the majority of p53
dependent genes (Brady et al., 2011). Interestingly, the TAD1 mutant is still capable of
tumor suppression despite being unable to induce apoptosis or cell cycle arrest. When
the TAD2 domain is mutated (F53Q, F54S), no major changes in the transcriptional
activity of p53 were found and at a glance this synthetic mutant appears to retain the
functions of WT p53. However, when both TAD1 and TAD2 are mutated, p53 loses all
transcriptional function and can no longer inhibit tumorigenesis, resembling a p53-null
phenotype (Brady et al., 2011). It is believed that these two domains act in a synergistic
fashion, rather than an additive fashion, and are both required for p53 to prevent
oncogenesis (Raj and Attardi, 2017).
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Figure 1.1: Domains of p53.
Structural organization of p53, with amino acid residue numbers labeled from amino-terminus to
carboxyl-terminus. The P47S variant occurs in TAD2.

1.2.3 p53 Activation
The p53 tumor suppressor protein has been dubbed the “Guardian of the
Genome”. It acts as a transcription factor and serves as a master regulator of hundreds
of target genes. Several transcription independent functions of p53 have also been
identified, for example p53 can promote apoptosis by interacting with Bcl-2 and Bcl-XL in
the mitochondria (Chipuk et al., 2004; Tomita et al., 2006). Additionally, p53 can directly
or indirectly repress transcription of certain genes such as SLC7A11, GLUT1 and Nanog
(Kaiser and Attardi, 2018).
There are several cellular stresses that can activate p53, such as DNA damage,
replication stress, oncogene activation, hypoxia, telomere erosion and nutrient
deprivation. Depending on the stress encountered, p53 will induce the appropriate
response that will halt the accumulation of oncogenic mutations and ultimately prevent
8

the initiation and spread of cancer (Figure 1.2). If damage to the cell is beyond repair,
p53 can eliminate the cell completely through a form of cell death, such as apoptosis or
ferroptosis. If the cell can be rescued, p53 can arrest the growth of a cell, presumably to
give the cell enough time to correct the damage that has been done and resume normal
proliferation after the mutation has been repaired (Kastenhuber and Lowe, 2017).
p53 controls a diverse range of responses, thus it is important to keep in mind
that the activation and function of p53 can be context dependent. For example, the
response of p53 depends on cell type, differentiation state, the activating stress,
epigenetic state, and tissue microenvironment. Post-translational modifications are also
important to consider when assessing p53 activity, as specific post-translational
modifications can alter the affinity of p53 for different target genes and trigger various
responses. For example, phosphorylation of the Ser46 site of p53 is key event
necessary for stimulating apoptosis (Smeenk et al., 2011). There are several other
modifications such as SUMOylation, glycosylation, acetylation, and prolyl isomerization
that occur throughout the p53 protein, and result in modifying protein stability and target
gene binding (Kastenhuber and Lowe, 2017). These multiple levels of control enable
p53 to selectively regulate different sets of target genes to ensure the cell will have the
optimal response to the specific stress that is encountered.

1.2.4 Canonical functions of p53
The most well-studied functions of p53 include controlling cell cycle arrest,
senescence and apoptosis. Upon DNA damage in the cell, DNA damage response
kinases phosphorylate and stabilize p53, enabling p53 to turn on the appropriate
downstream target genes (Williams and Schumacher, 2016). Initially p53 was found to
9

halt proliferation in response to DNA damage by inducing a brief G1 cell cycle arrest,
giving the cell time to correct any mutations that could lead to tumorigenesis (Kastan et
al., 1991). It was found that CDKN1A is key p53 target gene that drives this induced cell
cycle arrest, as this gene encodes the cyclin dependent kinase inhibitor p21 (Brugarolas
et al., 1995; Deng et al., 1995). When damage is irreparable and the cell must
permanently shut down, p53 can induce senescence through target genes such as
CDKN1A/p21, PAI-1 or PML. Alternatively, p53 can halt proliferation by inducing
apoptosis through target genes such as PUMA and NOXA (Kaiser and Attardi, 2018).
Though apoptosis, cell cycle arrest and senescence are widely regarded as the
predominant functions of p53, many studies have recently emerged demonstrating that
p53 can suppress cancer through other pathways. These other pathways regulated by
p53 include autophagy, metabolism, ferroptosis, cellular plasticity and pluripotency, ROS
control, inflammation, the epithelial-to-mesenchymal (EMT) transition, and angiogenesis
(Kastenhuber and Lowe, 2017).
Many studies have shown p53 promotes differentiation of stem cells and
suppresses the programming of somatic cells into pluripotent stem cells (Hong et al.,
2009; Marion et al., 2009). If cells exhibit less plasticity and are instead more
differentiated, it will result in a less plastic phenotype in young cancer cells and prevent
proliferation of cancer stem cells. There is also evidence that p53 opposes EMT and
restricts cancer cell invasion and metastasis to other sites. It has been shown that p53
downregulates transcription factors such as Snail1, Slug and Zeb, that are all crucial for
EMT (Kim et al., 2011; Wang et al., 2009). Several in vitro studies have demonstrated
that p53 plays a role in impeding motility and invasiveness of various cancer cell types
(Kaiser and Attardi, 2018). p53 has also been indicated in playing a role in immune
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response, by activating a subset of genes involved in immune cell recruitment and
surveillance. For example, in liver carcinoma it has been shown that p53 activation leads
to the transcription of cytokines such as Csf1 and Il15. The activation of these cytokines
will promote the recruitment of neutrophils, natural killer cells and macrophages, which in
turn will halt tumorigenesis (Xue et al., 2007).
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Figure 1.2: p53 activation and response.
p53 is activated by various stresses, indicated by the red words, and responds by turning on the
appropriate downstream response, as depicted by the green words.

1.3 Emerging roles of p53
1.3.1 p53 and metabolism
A major function of p53 that has been gaining momentum in recent years is the
ability of p53 to respond to metabolic stress and limit cell proliferation and growth.
Metabolic stresses that activate p53 tend to be more transient, such as hypoxia or low
nutrient availability. These stresses require a more adaptive response from the cell,
rather than complete shutdown of the cell that tends to occur when a genotoxic stress is
encountered (Berkers et al., 2013). A common feature of cancer cells is the ability to
reprogram metabolic pathways. Doing so enables a cancer cell to survive under adverse
conditions such as low nutrients or low oxygen, promotes the activation of anabolic
pathways, and can limit oxidative damage to the cell (Vousden and Prives, 2009).
Generally, p53 will oppose tumorigenesis by increasing catabolism and
decreasing proliferation. Glucose is one of the primary sources of energy for the cell and
cancer cells exhibit increased glucose consumption and increased glycolysis. p53 has
been shown to transcriptionally repress two of the major glucose transporters in the cell,
GLUT1 and GLUT4 (Schwartzenberg-Bar-Yoseph et al., 2004). It has been shown to
decrease glycolysis by inducing the transcription of RRAD and TIGAR, which are both
known inhibitors of glycolysis (Bensaad et al., 2006; Zhang et al., 2014). While p53
generally acts to suppress glycolysis, it is believed to increase oxidative phosphorylation.
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p53 transactivates the SCO2 gene, which encodes a protein that facilitates the transfer
of electrons during mitochondrial respiration (Matoba et al., 2006). p53 also
transactivates GLS2, which encodes an enzyme that catalyzes the conversion of
glutamine to glutamate, enabling glutamate to be used as an alternate energy source in
the mitochondria (Hu et al., 2010).
There are also transcription-independent functions of p53 that regulate
metabolism, as p53 can bind to and inhibit glucose-6-phosphate dehydrogenase
(G6PDH). G6PDH is an enzyme that catalyzes the rate limiting step of the pentose
phosphate pathway, using a product of glycolysis as a substrate. The pentose
phosphate pathway serves as a major source of NADPH generation. NADPH serves as
a key reducing agent for many reactions such as glutathione generation and de novo
lipid synthesis. The pentose phosphate pathway is found to be upregulated in cancer
cells, thus by inhibiting G6PDH, p53 is able to suppress cancer cell proliferation (Jiang et
al., 2011).
It is important to note that p53 can perform opposing functions on the same
metabolic process depending on the cell type (Kastenhuber and Lowe, 2017). Studies
have clearly demonstrated that p53 inhibits glycolysis in breast and lung cells by
repressing the expression of glycolytic enzymes (Kim et al., 2013) or by impeding
glucose uptake (Zhang et al., 2013). However, in muscle cells p53 induces glycolytic
enzymes resulting in increased glycolysis (Kruiswijk et al., 2015). Thus, when assessing
the role of p53 in metabolism, it is necessary to consider the context such as the stress
encountered, tissue location and other biochemical pathways that have been activated
(Figure 1.3).
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1.3.2 p53 and mTOR
mTOR (mechanistic target of rapamycin), is a serine/threonine kinase that serves
as a master regulator of metabolism and cell growth, and functions by phosphorylating
its downstream targets. This pathway is activated by environmental signals such as
nutrients and growth factors, thus levels of glucose and amino acids play an important
role in regulating mTOR activity. In addition to proliferation, mTOR is known to regulate
translation, ribosome biogenesis, autophagy, and cytoskeletal reorganization (Liu and
Sabatini, 2020b).

However, heightened mTOR activity can also contribute to

oncogenesis thus a delicate balance must be maintained between the mTOR and p53
pathways in order to balance the requirement for normal cell growth and stress response
(Hasty et al., 2013).
p53 target genes such as PTEN, LKB1 and TSC2 that are also tumor
suppressors have been found to be negative regulators of mTOR (Shaw et al., 2004).
The TSC2 subunit of the TSC1:TSC2 complex serves as a GTPase-activating protein for
the protein Rheb, which is a GTPase known to activate mTOR. Through this interaction,
TSC2 binds to and inhibits Rheb, thereby decreasing mTOR activity (Corradetti and
Guan, 2006; Hay and Sonenberg, 2004). AMPK-activated protein kinase (AMPK) is an
enzyme that monitors the ATP/AMP ratios in the cell and is activated under low nutrient
levels or energy stress (Feng et al., 2007; Feng et al., 2005). When nutrient levels fall
below a certain threshold, AMPK will phosphorylate and thereby activate TSC2 which
then shuts down mTOR activity. AMPKβ1 is a subunit of the AMPK complex which plays
an important role in regulating AMPK activity and localization within the cell (Warden et
al., 2001). It has been shown that AMPKβ1is a direct p53 target gene, further
highlighting how p53 negatively regulates the mTOR pathway (Feng et al., 2007). AMPK
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can also activate p53 by inducing phosphorylation of p53 at the serine 15 site (Jones et
al., 2005). Sestrin1 (SESN1) and Sestrin 2 (SESN2) are two p53 target genes that are
generally induced upon DNA damage and oxidative stress; however, both have also
been shown to inhibit mTOR signaling. These genes activate AMPK, which in turn will
phosphorylate TSC2 and stimulate its GAP activity, ultimately resulting in the inhibition of
mTOR. In vivo studies confirmed that Sestrin2-deficient mice are unable to inhibit mTOR
signaling upon genotoxic stress (Budanov and Karin, 2008). Taken together, these
studies demonstrate that there are multiple nodes connecting the p53 pathway to the
mTOR pathway and how a homeostasis must be maintained for optimal cell function.

1.3.3 p53 regulates lipid metabolism
Though p53 is well known for regulating metabolic pathways commonly studied
in cancer, such as glycolysis and the TCA cycle, p53 has also been shown to play a
major role in mediating lipid metabolism (Berkers et al., 2013). Wild-type and mutant
p53 regulate lipid metabolism on both the transcriptional level and on the protein-protein
interaction level (Parrales and Iwakuma, 2016). It is believed that p53 enhances fatty
acid oxidation while inhibiting fatty acid synthesis, thus acting as a negative regulator of
lipid synthesis.

Fatty acid oxidation involves the breakdown of fatty acids in the

mitochondria; this is one mechanism cells use to produce substrates such as NADH,
acetyl-CoA and FADH2 , which are subsequently used in the TCA cycle and electron
transport chain (Berkers et al., 2013). Sanchez-Macedo and colleagues demonstrated
that carnitine palmitoyltransferase 1C (CPT1C), an enzyme that aids in the transport of
activated fatty acids to the mitochondria, is expressed in a p53-dependent manner both
in vitro and in vivo and that Cpt1c deficient mice displayed delayed tumor development
and higher survival rates (Sanchez-Macedo et al., 2013). Lipin 1 (LPIN1) is a p53 target
15

gene necessary for proper adipocyte development and was found to be induced under
low nutrient conditions (Assaily et al., 2011). Using a series of gain-of-function and lossof-function experiments, Finck and colleagues showed that LPIN1 interacts with PGC1alpha, another known p53 metabolic target, and that this interaction activates the
expression of other genes involved in promoting fatty acid oxidation (Finck et al., 2006).
The sterol regulatory element-binding proteins (SREBP) family are a family of
transcription factors that modulate the expression of genes involved in cholesterol, fatty
acid, triacylglycerol and phospholipid synthesis, and is often upregulated in many types
of cancer (Ettinger et al., 2004; Guo et al., 2009; Parrales and Iwakuma, 2016).
Deleting p53 in ob/ob mice led to increased levels of SREBP-1 and downstream targets,
meanwhile ob/ob mice expressing p53 displayed low levels of SREBP-1 and
downstream targets, indicating that p53 represses SREBP-1 (Yahagi et al., 2003).
A microarray analysis of human liver-derived cells identified phospholipid transfer
protein (PLTP), ATP binding cassette A12 (ABCA12) and carboxyl ester lipase (CEL) as
three p53 target genes that all play a role in lipid transport (Goldstein et al., 2012). PLTP
is a secreted molecule bound to high-density lipoprotein (HDL) that transfers
phospholipids from very low-density lipoproteins (VLDL) and low-density lipoproteins
(LDL) to HDL particles in the liver, where reverse cholesterol transport occurs (Masson
et al., 2009). Both ABCA12 and ABCA5, another p53 target gene, have been shown to
mediate cholesterol efflux and both genes have been implicated in atherosclerosis (Fu et
al., 2013; Ye et al., 2010). CEL is an enzyme that hydrolyzes dietary lipids into fatty
acids and cholesterol and also plays a role in HDL uptake in the liver (Goldstein et al.,
2012). It is evident that p53 plays an important role in lipid shuttling as it regulates a
variety of genes that mediate lipid transport (Goldstein and Rotter, 2012). Though there
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is a clear role of p53 in mediating several genes that are essential for lipid metabolism,
many of these genes have not been directly shown to be involved in suppressing tumor
formation. The exact mechanism for how and when p53 induces many of these genes
remains to be uncovered, for example it is not known if p53 activates these genes in
response to metabolic stress or if basal levels of p53 are required to maintain lipid
homeostasis (Goldstein and Rotter, 2012). Some may argue that this implies the role of
p53 extends beyond a tumor suppressor, however one could also postulate that there
are other tumor suppressor functions of p53 involving lipids that have not been fully
explored.

Figure 1.3: Role of p53 in metabolism.
The role of WT p53 in metabolism. Genes positively regulated by p53 are shown in green, genes
negatively regulated by p53 are shown in red. p53 inhibits glucose transport, glycolysis and fatty
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acid synthesis while it promotes lipid uptake, fatty acid oxidation, oxidative phosphorylation and
glutaminolysis.

1.3.4 Ferroptosis
In 2012, Dixon and colleagues discovered a novel form of regulated cell death
called ferroptosis, which is best described as an iron-dependent, caspase-independent
form of cell death resulting from the accumulation of lipid reactive oxygen species (Dixon
et al., 2012; Yang et al., 2014). This process is driven by the inactivation of glutathione
peroxidase 4 (GPX4), an enzyme that is responsible for converting lethal lipid
hydroperoxides to non-toxic lipid alcohols and requires glutathione to function (Yang et
al., 2014).

Ferroptosis is commonly induced using either erastin or 1S,3R-RSL3

(hereafter referred to as RSL3). Erastin inhibits the cystine/glutamate antiporter
SLC7A11, which results in depleted glutathione and subsequent inactivation of GPX4.
RSL3 directly binds to and inhibits GPX4, resulting in the induction of ferroptosis (Dixon
et al., 2012; Jiang et al., 2015; Yang et al., 2016).
It is believed that peroxidation of polyunsaturated fatty acids (PUFAs) is the
stimulus that drives ferroptosis. PUFAs contain bis-allylic protons that can easily be
abstracted and produce radicals that will react with oxygen, creating more radicals and
resulting in a chain reaction of lipid ROS (Yang et al., 2016). The exact mechanism of
cell death remains unknown, however one hypothesis is that the lipid damage leads to
the destruction of the cell membrane (Magtanong et al., 2016). It has been postulated
that ferroptosis could be another mechanism of tumor suppression by eliminating cells
that are nutrient deprived or have been exposed to an environmental stress or infection.
Death by ferroptosis can be prevented by suppressing lipid peroxidation, which can be
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accomplished by using lipophilic antioxidants such as ferrostatin-1 or Vitamin E, as well
as by using iron chelators or depleting PUFAs (Stockwell et al., 2017).

1.3.5 The role of p53 in the regulation of ferroptosis has been controversial
Wei Gu’s research group developed a mouse model in which three normally
acetylated lysine residues in the DNA binding domain of p53 were mutated to arginine,
hereafter referred to as the 3KR model. The 3KR mouse lost the ability to undergo
apoptosis, cell cycle arrest and senescence, and failed to transactivate the majority of
p53 target genes. Interestingly, this mouse model did not develop cancer implying p53
has an alternate mechanism of tumor suppression (Li et al., 2012). It was found that the
mutant p53 3KR fully retains the ability to undergo ferroptosis and regulate cystine
metabolism by repressing SLC7A11 expression, thus explaining the observed
phenotype. When wild-type and 3KR MEFs were treated with the ferroptosis inducer,
erastin, almost 50% cell death was observed whereas p53 null MEFs exhibited only 20%
cell death, indicating that p53 sensitizes cells to ferroptosis. Perhaps the most
compelling piece of data that ferroptosis is key to p53 function was the phenotype of
p533KR/3KRMdm2-/- embryos treated with ferrostatin-1. Prior studies have demonstrated
that apoptosis, cell cycle arrest and senescence cause lethality in p53+/+Mdm2-/- yet
interestingly, the p533KR/3KRMdm2-/-, which retains the ability to undergo these processes,
were still unable to bear offspring. After treating the p533KR/3KRMdm2-/- embryos with
ferrostatin-1, it was found that the embryos were significantly larger with more welldeveloped physiology compared to the untreated embryos, thus demonstrating p53
mediated ferroptosis is what drives embryonic lethality in the 3KR model (Jiang et al.,
2015).
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An additional acetylation site was identified at K98, and a 4KR mouse model was
developed. Mutating this single residue from a lysine to arginine had very little effect on
p53 mediated transactivation of downstream targets, however mutating this residue in
addition to the three lysine residues in the 3KR model completely ablated the ability of
p53 to regulate its metabolic targets, including SLC7A11. Unlike the 3KR model, the
4KR model is unable to suppress tumor growth in mouse xenograft models and lost the
ability to induce ferroptosis (Wang et al., 2016). Taken together, these results indicate
that p53 plays an important role in mediating ferroptosis and that p53 acetylation can
dictate ferroptotic responses and tumor suppression.
Other p53 target genes associated with ferroptosis include PTGS2, SAT1 and
GLS2 (Gao et al., 2015; Ou et al., 2016; Yang et al., 2014). PTGS2 is significantly
upregulated upon ferroptotic induction and is often used as a marker of ferroptosis,
however the exact role and function remain unclear (Yang et al., 2014). Activation of
SAT1 was found to sensitize cells to ferroptosis and induce lipid peroxidation through
regulating the lipoxygenase ALOX15 (Ou et al., 2016). GLS2 converts glutamine to
glutamate and knockdown of GLS2 was found to completely inhibit ferroptosis in MEFs
(Gao et al., 2015; Jennis et al., 2016).
Though many studies suggest that p53 plays a role in enhancing ferroptosis
sensitivity, several groups have shown that under certain contexts, p53 can actually
suppress ferroptosis. In work by Xie et al., the authors demonstrate that p53 functions in
a transcription-independent manner by binding to and sequestering dipeptidyl-peptidase4 (DPP4). This results in nuclear accumulation of DPP4 and renders it inactive. Upon
loss of p53, DPP4 is able to localize to the plasma membrane and facilitate lipid
peroxidation, ultimately contributing to ferroptotic cell death (Xie et al., 2017).
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Tarangelo and colleagues also published evidence that p53 may negatively
regulate ferroptosis (Tarangelo et al., 2018). It was found that pre-treating cells with
Nutlin-3, a compound used to stabilize p53, for 48 hours prior to treating cells with a
ferroptosis inducer delayed the onset of ferroptosis in several cell types. The delayed
onset of ferroptosis was found to depend on CDKN1A (encoding p21), a critical p53
transcriptional target. The mechanism through which p21 delays ferroptosis has yet to
be elucidated, however cell cycle arrest due to CDK 4/6 inhibition and enhanced NRF2
activity were excluded as a part of this mechanism.

It was found that there is an

increase in glutathione production during the pre-treatment phase, and it is believed that
the conservation of intracellular glutathione is another contributing factor for reduced
ferroptosis sensitivity. The authors concluded that the p53-p21 axis enables cancer cells
to survive under conditions of metabolic stress, such as cystine deprivation, by
suppressing the onset of ferroptosis (Tarangelo et al., 2018).
Work by the Prives group has shown that MDM2 and MDMX, known negative
regulators of p53 activity, promote ferroptosis in a p53-independent manner. The MDM2MDMX complex was found to alter the lipid profile of cells through regulating PPARα
activity and suppressing the antioxidant response of cells. This work supports the
premise that ferroptotic regulation extends beyond the p53 axis (Venkatesh et al., 2020).
A role for p53 in the regulation of metabolism is quite clear: WT p53 limits
glucose metabolism and lipid synthesis, while mutant p53 appears to do the opposite.
The contribution of this activity to tumor suppression by p53, and to the ability of mutant
p53 to drive tumor progression, remains to be unequivocally proven. However, the role
of p53 in the regulation of ferroptosis, and the contribution of this function to tumor
suppression is even less clear. While compelling data from mouse models support the
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premise that p53 regulates the sensitivity of cells to ferroptosis, this may be restricted to
the ability of basal p53 to suppress spontaneous tumor development, and in oncogenestressed mouse models it is clear that senescence and apoptosis play the predominant
role. Similarly, p53 may regulate ferroptosis sensitivity in a cell type-specific manner.
More studies in animal models, with attention to ferroptosis in different tissues, need to
be done to more fully understand the role of p53 in ferroptosis, and ferroptosis in tumor
suppression.

Additionally, a clearer idea of what p53-target genes play a role in

sensitivity to ferroptosis needs to be attained (Figure 1.4).

Figure 1.4: Various roles of p53 in ferroptosis.
Ferroptosis is driven by inhibition of GPX4, the enzyme that catalyzes the conversion of
polyunsaturated fatty acids containing peroxides (depicted by red dots) to alcohols. Depending on
the context, p53 can suppress ferroptosis or promote ferroptosis. Mutant p53 sensitizes cells to
ferroptosis even more than WT p53.
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1.3.6 The African-specific P47S variant
A naturally occurring polymorphism in TP53 was reported in TAD2 at codon 47,
in which a proline is replaced by a serine (P47S, rs1800371) (Felley-Bosco et al., 1993).
This SNP, hereafter referred to as S47, was reported over two decades ago and is found
predominantly in people of African and African American descent, with a frequency of
about 6-8% in Africans and 1.5% in African Americans (Jennis et al., 2016). This SNP is
also present in Hispanic populations and has not been reported in Caucasian
Americans. Our group showed that women of African ancestry who carried the S47
allele had a higher risk of developing pre-menopausal breast cancer, with a per allele
odds ratio of 1.72 (Murphy et al., 2017). It is believed that there may be a correlation
between this SNP and other types of cancer in African descent populations; however
due to the dearth of large sample or data sets from African descent populations, such
associations await determination.
Interestingly, this polymorphism is adjacent to a key phosphorylation site in p53
located at the Serine 46 residue. The Serine 46 site is phosphorylated by proline
directed kinases including p38 MAPK, HIPK2 and DYRK, and this phosphorylation event
has been shown to be very important for p53’s ability to induce apoptosis (Bulavin et al.,
1999; Felley-Bosco et al., 1993; Hofmann et al., 2002). In-vitro kinase assays revealed
that cells containing the S47 variant are impaired for phosphorylation at the Ser46 site
by proline directed kinases, such as purified p38MAPK. It was also found that cells
containing this variant have a 5-fold decreased ability to undergo cell death when
compared to cells containing WT P47 form of p53 (Li et al., 2005).
To further study the biological consequences of this variant, our lab generated a
knock-in mouse model using a humanized p53 knock-in (Hupki) containing the S47
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allele. This humanized version of p53 replaces mouse exons four through nine with the
corresponding human p53 exons (codon 32-332). Mice with the homozygous S47 allele
spontaneously developed cancer between 12 to 18 months of age, and heterozygous
mice were also found to be susceptible to cancer. The most common cancer type
observed was hepatocellular carcinoma, however B-cell lymphoma, histiocytic sarcoma,
colorectal carcinoma and pancreatic ductal adenocarcinoma were also observed. The
S47 mouse phenotype is distinct from Li-Fraumeni mouse models generated by Lozano
and Jacks, which develop more epithelial cancers (Lang et al., 2004; Olive et al., 2004).
It is also very distinct from the p53 knockout mouse, which develops T cell lymphoma
and sarcoma (Basu and Murphy, 2016).
Both WT and S47 cells exhibit similar transcriptional function, however gene
expression studies revealed that S47 is impaired in its ability to transactivate Gls2 and
Sco2, two genes that play a key role in cellular metabolism. Cells containing the S47
variant are also found to have impaired apoptosis when confronted with various
genotoxic stresses, particularly cisplatin. In addition to a defect in apoptosis, it was found
that S47 cells are markedly resistant to ferroptosis (Jennis et al., 2016). The
cystine/glutamate antiporter SLC7A11 plays a key role in regulating ferroptosis, as
cystine is a precursor to cysteine and glutathione. Excess glutamate or treatment with
erastin prevents cystine uptake, leading to decreased accumulation of intracellular
cysteine and glutathione, resulting in ferroptotic cell death. WT p53 has been shown to
repress SLC7A11, thereby preventing the import of cystine and inducing ferroptosis
(Jiang et al., 2015). We have observed that the S47 variant is impaired for repression of
SLC7A11, and ChIP studies have indicated decreased binding of the S47 protein at the
p53 binding site on the SLC7A11 promoter region. S47 MEFs were found to be 27-fold
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resistant to erastin-induced ferroptosis, and S47 LCLs were found to be 19-fold resistant
to RSL3-induced ferroptosis. Ptgs2 transactivation and GPX4 degradation, both key
markers of ferroptotic induction, were shown to be impaired in S47 cells. This significant
ferroptotic defect is believed to be the primary reason for impaired tumor suppression in
S47 mice and highlights the role of p53 in regulating ferroptosis sensitivity as a
mechanism of tumor suppression (Jennis et al., 2016) (Figure 1.5).
The ferroptotic defect in S47 cells can be attributed to elevated levels of
intracellular antioxidants in S47 (Leu et al., 2019). Metabolomic analyses revealed S47
cells have increased levels of low molecular weight thiols including Coenzyme A (CoA)
and glutathione (GSH). Increased levels of GSH were also observed in S47 livers,
confirming that this phenotype has in vivo relevance. Antioxidants such as CoA and
GSH affect the redox environment of the cell, particularly affecting cysteine residues in
proteins. There are several proteins that are sensitive to redox regulation and can adopt
an altered conformation when this redox state is altered. p53 contains conserved
cysteine residues at or near the DNA binding domain, and under normal conditions, the
reduced cysteine residues enable tetramerization and subsequent activation of the p53
protein. However, upon oxidation, the cysteine residues will form bonds with other thiol
groups and prevent proper oligomerization of the protein. It was found that the higher
levels of CoA and GSH feedback on p53, directly impacting structure and function of the
protein. By modulating the redox state using reagents such as diethyl maleate or
exogenous CoA, it is possible to manipulate p53 conformation and ferroptosis sensitivity
(Leu et al., 2019; Leu et al., 2020). These findings are broadly consistent with data by
Tarangelo, showing that conservation of glutathione is correlated with ferroptosis
inhibition (Tarangelo et al., 2018).
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Singh et al. demonstrated that the defect in ferroptosis results in iron
accumulation in S47 macrophages, which ultimately results in more severe bacterial
pathogenesis and greater susceptibility to Listeria infection. However, it was found that
mice bearing the S47 variant show an improved response to malarial toxin hemozoin,
suggesting that S47 might have provided an advantage in sub-Saharan Africa where
there is a high risk of malaria. The ferroptotic defect has also been found to contribute to
a higher risk of hereditary hemochromatosis in African Americans who carry this SNP
(Singh et al., 2020).

Figure 1.5: The S47 mouse.
Unlike mice bearing WT p53, the S47 mouse is impaired for tumor suppression, cisplatin
mediated apoptosis and ferroptosis.
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1.4 Thesis objectives

The aim of this dissertation is to explore the function of the S47 variant of TP53
and to use this variant as a tool to better understand tumor suppression and ferroptosis.
In Chapter 2, I describe the unique metabolic phenotype that was observed in S47 mice.
I found that S47 cells and mice exhibit increased mTOR activity, ultimately stemming
from an impaired protein-protein interaction due to the altered redox state. Our data
support the premise that this increase in mTOR activity contributes to the increased size
and superior metabolic efficiency observed in S47 mice. We hypothesize that the
superior metabolic efficiency might have once provided an evolutionary fitness
advantage, which could explain why the S47 variant remains in the population despite
predisposing carriers to cancer. In Chapter 3, I describe how I used the S47 variant to
identify a p53 target gene, PLTP, as a negative regulator of ferroptosis in liver cancer
cells. An RNA-Seq experiment comparing WT and S47 cells led us to identify PLTP as
significantly repressed in S47. I performed a series of assays to show that this gene
contributes to ferroptosis resistance and demonstrate that the mechanism is due to
increasing lipid storage, which sequesters lipids and prevents them from undergoing
peroxidation at the cell membrane. To conclude, Chapter 4 provides a summary of both
studies and discusses avenues for further studies on this work.
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CHAPTER 2: Increased mTOR Activity and Metabolic Efficiency Found in the P47S
Variant of TP53

This chapter has been adapted from the following manuscript:
Gnanapradeepan K, Basu S, Barnoud T, Leu JIJ, Good M, Lee J, Quinn WJ,
Kung CP, Ahima R, Baur J, Wellen K, Schug Z, George DL and Murphy ME.
Increased mTOR activity in mice with the tumor prone S47 variant of p53 confers
enhanced size, metabolism and fitness. eLife (2020);9:e55994

2.1 Abstract

The Pro47Ser variant of p53 (hereafter S47) exists in African-descent populations and is
associated with increased cancer risk in humans and mice. This variant shows impaired
repression of the cystine importer Slc7a11. Consequently, S47 cells possess increased
cysteine and glutathione (GSH) accumulation compared to cells with wild type p53. In
this study we show that mice containing the S47 variant have increased mTOR activity,
increased oxidative metabolism, larger size, and improved metabolic efficiency.
Mechanistically, we show that there is increased association between mTOR and its
positive regulator Rheb in S47 cells, due to altered redox state of GAPDH, which
normally binds and sequesters Rheb. Compounds that decrease glutathione in S47
cells normalize GAPDH-Rheb complex formation and mTOR activity. The enhanced
metabolic efficiency may have been selected for in early Africa, making the S47 variant
one of a growing number of cancer-predisposing genetic variants that possesses other
positive, potentially selectable attributes.
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2.2 Introduction

The p53 tumor suppressor protein serves as a master regulator of the cellular
response to intrinsic and extrinsic stress. Mutations in the TP53 gene occur in more
than 50% of human cancers, and this gene is well-known as the most frequently mutated
gene in cancer (Hollstein et al., 1991). p53 works to suppress uncontrolled cellular
growth and proliferation through various pathways including apoptosis, senescence, cell
cycle arrest and ferroptosis (Stockwell et al., 2017; Vousden and Prives, 2009). More
recently a role for p53 in the control of metabolism has emerged.

The metabolic

functions of p53 include the regulation of mitochondrial function, autophagy, cellular
redox state, and the control of lipid and carbohydrate metabolism; for review see
(Berkers et al., 2013; Gnanapradeepan et al., 2018).
As an integral part of its control of metabolism, p53 negatively regulates the
activity of mTOR (mammalian target of rapamycin), which is a master regulator of
metabolism in the cell. mTOR is a serine-threonine protein kinase that is stimulated by
mitogenic signals, and phosphorylates downstream targets that in turn regulate protein
synthesis and cell growth (Ben-Sahra and Manning, 2017). mTOR exists in two distinct
signaling complexes: mTORC1 is primarily responsible for cell growth and protein
synthesis, while mTORC2 plays roles in growth factor signaling, cytoskeletal control and
cell spreading (Liu and Sabatini, 2020a). Not surprisingly, mTOR activity is frequently
upregulated in a diverse range of cancers. p53 negatively regulates the mTOR pathway
in part through transactivation of the target genes PTEN, TSC2, PRKAB1 and
SESN1/SESN2 (Budanov and Karin, 2008; Feng et al., 2005). The regulation of mTOR
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by p53 is believed to couple the control of genome integrity with the decision to
proliferate (Hasty et al., 2013).
TP53 harbors several functionally impactful genetic variants or single nucleotide
polymorphisms (SNPs) (Basu et al., 2018; Jennis et al., 2016; Kung et al., 2016). A
naturally occurring variant in TP53 exists at codon 47, encoding serine instead of a
proline (Pro47Ser, rs1800371, G/A).

This variant exists predominantly in African-

descent populations and occurs in roughly 1% of African Americans and 6% of Africans
from sub-Saharan Africa (Murphy et al., 2017).

The S47 variant is associated with

increased risk for pre-menopausal breast cancer in African American women (Murphy et
al., 2017). In a mouse model, the S47 mouse develops markedly increased incidence of
spontaneous cancer, particularly hepatocellular carcinoma (Jennis et al., 2016). This
variant is likewise defective in the regulation of the small subset of p53 target genes that
play roles in ferroptosis sensitivity, including the cystine importer SLC7A11. As a result,
increased levels of cysteine and glutathione (GSH) accumulate in cells from S47
humans and mice (Jennis et al., 2016; Leu et al., 2019). More recently, we showed that
the ferroptotic defect in S47 mice leads to iron accumulation in their livers, spleens and
macrophages.

We also showed that the S47 variant is positively associated with

markers of iron overload in African Americans, such as increased levels of saturated
transferrin (Singh et al., 2020).
An emerging paradigm in the cancer literature is that tumor-predisposing genetic
variants may paradoxically provide selection benefit to individuals, thus potentially
explaining the frequency of these damaging alleles in the population. As an example,
women carrying tumor-predisposing mutations in the BRCA1 gene tend to be physically
larger and show increased fertility (Smith et al., 2012). Here-in we show that mice
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carrying a knock-in S47 allele in a pure C57Bl/6 background show increased size, lean
content (muscle), and metabolic efficiency, relative to littermate mice with WT p53. We
report that mouse and human S47 cells show a significant increase in mTOR activity,
due in part to increased mTOR-Rheb binding in S47 cells. We propose that these
attributes may have led to a positive selection for this variant in sub-Saharan Africa. Our
studies shed further light on the intricate regulation that exists between p53, mTOR
activity and metabolic output, in this case mediated by GSH and the control of cellular
redox state.

2.3 Results
2.3.1 Higher basal mTOR activity in cells containing the S47 variant
We previously showed that human lymphoblastoid cells (LCLs) that are
homozygous for the S47 variant of p53 are impaired for the transactivation of less than a
dozen p53 target genes, compared to cells from family members with WT p53 (Jennis et
al., 2016). We noted that several of these genes encode proteins that play roles in the
negative regulation of mTOR (Budanov and Karin, 2008; Feng et al., 2007).

We

confirmed via qRT-PCR that S47 LCLs show modestly decreased expression of the p53
target genes SESN1 and PTEN, and decreased transactivation of PRKAB1, relative to
WT cells following cisplatin treatment (Supplemental Figure 2.1A and 2.1B).

These

findings prompted us to assess basal mTOR activity in WT and S47 LCLs, and in MEFs
from WT and S47 mice. To corroborate our findings, we also analyzed tissues from
humanized p53 knock-in (Hupki) mice carrying WT and S47 alleles on a pure C57Bl/6
background, which we previously generated and characterized (Jennis et al., 2016).
Western blot analysis of WT and S47 LCLs, along with multiple clones of WT and S47
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MEFs, revealed increased p-S6K1 (Thr389) in S47 cells; following normalization to total
S6K1, this increase ranged between 2-3 fold (Figure 2.1A-B). We next compared ageand sex-matched pairs of lung and muscle tissue from WT and S47 mice, because
mTOR activity is influenced by age and gender, with increased mTOR activity in female
and older mice (Baar et al., 2016). We found increased levels of p-S6K1 (T389) and pmTOR (Ser2448) in S47 lung and skeletal muscle, relative to WT tissues (Figure 2.1C
and D). Immunohistochemical analysis of tissues from multiple age- and sex-matched
WT and S47 mice confirmed these findings (Figure 2.1E).

Interestingly, increased

mTOR activity was not seen in all tissues of the S47 mouse (Supplemental Figure 2.1C),
and lung and skeletal muscle were the most consistently different between WT and S47.
We also did not detect significant differences in p-AKT (Ser473) in WT and S47 cells,
suggesting that mTORC1 and not mTORC2 is likely responsible for the observed
differences in mTOR activity (Supplemental Figure 2.1D).
We next sought to test the kinetics of mTOR activation in WT and S47 cells by
subjecting early passage WT and S47 MEFs to nutrient deprivation, followed by
monitoring of mTOR activation markers after nutrient restoration using antisera to pS6K1 and p-mTOR. Glucose deprivation experiments revealed consistent but modestly
increased p-S6K1 following glucose refeed in S47 MEFs, compared to WT (Figure 2.1F),
while serum deprivation experiments revealed more pronounced results. For serum
deprivation, we subjected three independent cultures each of WT and S47 MEFs to
0.1% serum for 16 hours, followed by 10% serum, after which total and phospho -S6K1
and -mTOR were monitored in a time course. S47 cells consistently showed increased
induction of markers of mTOR activation after serum re-feed compared to WT cells
(Figure 2.1G). We next performed amino acid deprivation experiments; these likewise
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showed increased response in S47 cells (Supplemental Figure 2.1E).

Combined

densitometry results from all forms of nutrient deprivation revealed an approximately 2 to
3-fold increase in p-S6K1 in S47 cells following nutrient restoration at 30 or 60 minutes
(Supplemental Figure 2.1F).
Given that mTOR plays a role in autophagy inhibition (Jung et al., 2010; White et
al., 2011), we wondered whether basal autophagy or autophagic flux might be
decreased in S47 cells. We were unable to see any differences in the steady state
levels of LC3B or the autophagy adaptor protein p62SQSTM1 in WT and S47 MEFs or
tissues, either at steady state (Supplemental Figure 2.1G) or following HBSS treatment
to induce autophagy (Supplemental Figure 2.1H). Likewise, we failed to see differences
in autophagic flux (conversion of LC3-I to LC3-II when the lysosome is inhibited;
Supplemental Figure 2.1I) between WT and S47 cells, or in cell viability after HBSS
treatment (Supplemental Figure 2.1J). Therefore, while markers of mTOR activity are
clearly increased in S47 cells and tissues, this does not appear to be accompanied by
alterations of basal or induced autophagy.
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Figure 2.1: Increased markers of mTOR activity in S47 cells and tissues.
(A) Western blot analyses reveal higher phospho-S6K1 expression in S47 LCLs and S47 MEFs,
obtained from two separate embryos per genotype. (B) Densitometry quantification of phosphoS6K1 protein expression in WT and S47 MEFs from 4 independent experiments; all values
normalized to total S6K1. Error bars represent standard error, (*) p value < 0.05. (C) Whole cell
lysates were extracted from 3 WT and 3 S47 mouse lungs and analyzed by Western blot for the
proteins indicated. Pair 1 and 3 are lungs isolated from male mice, pair 2 are lungs isolated from
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female mice. Densitometry quantification of phospho-S6K1 and phospho-mTOR was performed
and normalized to total S6K1 and total mTOR protein expression, respectively. (D) Whole cell
lysates were extracted from WT and S47 mouse skeletal muscle and analyzed as described
above. Densitometry quantification of phospho-S6, phospho-S6K1, phospho-mTOR was
performed and normalized to total S6, total S6K1 and total mTOR protein expression,
respectively.

(E) Immunohistochemical analysis of hematoxylin and eosin (H&E), phospho-

mTOR and phospho-S6K1 in WT and S47 mouse lung and skeletal tissue.

Data are

representative of n = 4 fields per genotype. Scale bar represents 100 μM. (F) WT and S47 MEFs
were starved in media containing no glucose for 16 hours, then media containing 4.5 g/L glucose
was re-introduced. Samples were collected at indicated time points and analyzed by Western blot
for p-S6K1, total S6K1 and GAPDH. (G) WT and S47 MEFs were starved in media containing
0.1% FBS for 16 hours, then media containing 10% serum was re-introduced and samples were
collected at indicated time points. Cell lysates were extracted from samples and subjected to
Western blot analysis for the proteins indicated.

2.3.2 Enhanced mitochondrial function and glycolysis in S47 cells
To determine the functional consequences of the increased markers of mTOR
activity in S47 cells, we used a Seahorse BioAnalyzer to assess the oxygen
consumption rate (OCR), as well as basal and compensatory glycolytic rate in WT and
S47 MEFs and LCLs. Seahorse analyses revealed that S47 LCLs show increased OCR
under stressed conditions compared to WT (Figure 2.2A).

Seahorse analyses also

revealed that human S47 LCLs and mouse S47 MEFs both show increased basal and
compensatory glycolysis, compared to WT cells (Figure 2.2B and C). We next assessed
glucose and glutamine consumption using a Yellow Springs Instrument (YSI) Analyzer.
These analyses revealed that S47 cells show significantly increased consumption of
glucose and glutamine, along with increased production of lactate and glutamate,
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compared to WT cells (Figure 2.2D and E). S47 cells do not proliferate more quickly
than WT cells (Jennis et al., 2016), suggesting that this increased nutrient consumption
may be used for biomass instead of proliferation. Interestingly, LCLs from individuals
heterozygous for the S47 variant (S47/WT), and MEFs from S47/WT mice, showed
values typically intermediate between homozygous WT and S47 cells (Figure 2.2D and
E). We next performed metabolic flux analyses in WT and S47 cells using
glucose. Analysis of

13

13

C-labeled

C6-glucose tracing in WT and S47 MEFs provided evidence for a

higher contribution of glucose carbon into the TCA cycle in S47 cells compared to WT
cells, as evidenced by increased labeling of citrate, malate, aspartate and glutamate in
S47 MEFs (Supplemental Figure 2.2A-D). We reasoned that one possibility for the
increased metabolism in S47 cells might be due to increased mitochondrial content,
which is regulated by mTOR (Morita et al., 2013). However, MitoTracker analyses and
Western blotting for mitochondrial proteins revealed no obvious increase in
mitochondrial content in S47 cells (Supplemental Figure 2.2E and F).
Because mTOR is known to regulate mitochondrial function (Morita et al., 2013;
Schieke et al., 2006; Ye et al., 2012), we next assessed the impact of mTOR inhibitors
on mitochondrial function in WT and S47 cells. Seahorse analysis of WT and S47 LCLs
revealed that S47 cells are less susceptible to inhibition of oxygen consumption rate and
maximal respiration by mTOR inhibitors rapamycin (Figure 2.3A and B) and Torin1
(Figure 2.3C and D). This finding was not due to altered efficacy of each inhibitor, as
evidenced by similar decreases in p-mTOR and p-S6 in WT and S47 cells following
treatment with rapamycin (Supplemental Figure 2.3A) and Torin1 (Figure 2.3E), and by
the finding that very high concentrations of Torin1 were able to inhibit oxygen
consumption equally well in both WT and S47 cells (Supplemental Figure 2.3B). The
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combined data support the premise that S47 cells possess enhanced metabolism
compared to WT cells.
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Figure 2.2: Increased metabolism in S47 cells compared to WT cells.
(A) Oxygen consumption rates (OCR) in WT and S47 LCLs were assessed using the Seahorse
XF Mito Stress Test. OCR was measured first in basal conditions, and following oligomycin,
FCCP and finally rotenone/antimycin. The bar graph depicts maximal OCR after FCCP injection
at ~ 40 minute timepoint; data are representative of three independent experiments performed
with at least six technical replicates, presented as mean ± SD. (B-C) Basal and compensatory
glycolysis in WT and S47 LCLs (B) and MEFs (C) were assessed using the Seahorse Glycolytic
Rate Assay.

Basal glycolysis is first measured, followed by treatment of cells with

rotenone/antimycin and 2-deoxy-D-glucose (2-DG). The bar graph depicts basal glycolysis at ~1
minute timepoint and compensatory glycolysis after antimycin/rotenone injection at ~ 22 minute
timepoint; data are representative of 3 independent experiments performed with at least ten
technical replicates. Bar graphs are presented as mean ± SD for all Seahorse analyses. (D-E)
Consumption of glucose and glutamine from media and production of lactate and glutamate were
analyzed from homozygous WT, heterozygous WT/S47 and homozygous S47 human LCLs (D)
and primary MEFs (E) using a YSI-7100 Bioanalyzer. Means and SEM are shown (n= 5).
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Figure 2.3: S47 mitochondria show decreased sensitivity to mTOR inhibition.
(A) Oxygen consumption rate (OCR) as measured by the Seahorse XF Mito Stress Test in WT
and S47 LCLs treated with 200 nM of rapamycin for 24 hours. (B) Bar graph depicts maximal
OCR after FCCP injection at ~ 40 minute timepoint; fold changes between rapamycin treated and
untreated samples are shown. Data are representative of 2 independent experiments performed
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with at least ten technical replicates. (C) OCR as measured by the Seahorse XF Mito Stress Test
in WT and S47 LCLs treated with 100 nM of Torin1 for 24 hours. (D) Bar graph depicts maximal
OCR after FCCP injection at ~ 40 minute timepoint; fold changes between Torin1 treated and
untreated samples are shown. Data are representative of 2 independent experiments performed
with at least eight technical replicates. (E) WT and S47 LCLs were treated with 100 nM of Torin1,
harvested at indicated time points after treatment and analyzed for the shown mTOR markers via
Western blot.

Because mTOR can regulate both cell size and protein translation, we were
careful to normalize to both cell number and protein content.

For example, when

comparing metabolic changes using the Seahorse assay, the results were standardized
to total cell number. When quantifying differences in mTOR activity, the results were
normalized to total protein content. In addition, phospho-S6K1 was normalized to total
S6K1 in each sample

2.3.3 Increased mTOR activity in S47 is due to increased mTOR-Rheb interaction
We next sought to identify the mechanism underlying increased mTOR activity in
S47 cells. Although we identified decreased mRNA levels of some mTOR regulators in
S47 cells, we found no evidence for differences at the protein level of any p53-induced
mTOR regulators in steady state MEFs (Supplemental Figure 2.4A) or following
treatment with Nutlin to induce p53 (Supplemental Figure 2.4B). Therefore, we analyzed
a key regulator of mTOR activity, the small GTPase Rheb, which binds and activates
mTOR (Long et al., 2005). We monitored the mTOR-Rheb association in WT and S47
MEFs using the technique of proximity ligation assay (PLA), which quantitatively detects
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protein-protein interactions.

PLA experiments revealed that there were consistently

increased mTOR-Rheb complexes in S47 cells, compared to WT; this was true in
multiple replicates, in multiple MEF clones, and using single antibody controls that
showed no signal (Figure 2.4A). Quantification of multiple experiments revealed an
approximately two-fold increase in mTOR-Rheb complexes in S47 cells compared to WT
(Figure 2.4B).
A recently-identified regulator of the mTOR-Rheb interaction is the cytosolic
enzyme GAPDH. This enzyme binds to Rheb and sequesters it from mTOR in cultured
cells, in a manner that is regulated by glucose levels (Lee et al., 2009).

First, we

confirmed that the interaction between Rheb and GAPDH is detectable in the skeletal
muscle of mice using IP-western, and that this interaction is regulated by glucose
(Supplemental Figure 2.4C). Next, we performed immunoprecipitation (IP)-western of
skeletal muscle extracts from WT and S47 mice; we found that there was increased
mTOR, and significantly decreased GAPDH, in Rheb IPs from S47 skeletal muscle
compared to WT (Figure 2.4C). The combined data from three independent IPs of Rheb
in WT and S47 skeletal muscle revealed an approximately 2-fold decrease in the amount
of GAPDH co-precipitating with Rheb in S47 skeletal muscle compared to WT (p<0.05,
Figure 2.4D). In contrast there were no differences in the levels of mTOR, Rheb and
GAPDH in these extracts (Figure 2.4C – WCL, Supplemental Figure 2.4D). Consistent
with these IP-western findings, PLA analyses corroborated that the GAPDH-Rheb
association is markedly decreased in S47 MEFs relative to WT MEFs (Figure 2.4A).
Confocal microscopy analyses revealed no significant differences in the cellular
localization of Rheb at the lysosome, as assessed by LAMP1 localization, nor were there
any differences in TSC2 localization at the lysosome in WT and S47 MEFs
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(Supplemental Figure 2.4E). The combined data support the premise that the increased
mTOR activity in S47 cells is due to increased Rheb-mTOR association, along with a
decreased Rheb-GAPDH association.
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Figure 2.4: Increased mTOR-Rheb binding in S47 cells is due to decreased GAPDH-Rheb
binding
(A-B) An in situ proximity ligation assay (PLA) was performed in WT and S47 MEFs. Each red
dot represents an interaction between mTOR-Rheb or GAPDH-Rheb as indicated; scale bar
represents 50 μM. The samples were counterstained with DAPI to detect nuclei. Cells stained in
the absence of one primary antibody were used as a negative control. (B) Quantification of the
mTOR-Rheb interactions, measured as the average number of PLA signals per nuclei. Data
were quantified by counting the number of cells in five random fields per experimental condition.
(***) p-value < 0.001, Student’s t-test. (C) Lysates extracted from WT and S47 skeletal tissue
were immunoprecipitated with anti-Rheb. The amount of co-precipitating mTOR and GAPDH, as
well as immunoprecipitated Rheb, were assessed by Western blot. Whole cell lysate (WCL) is
shown on the right. (D) Quantification of the amount of GAPDH bound to Rheb, divided by total
Rheb pulled down, in WT and S47 skeletal tissue, n = 3 independent experiments, (*) p-value <
0.05.

GAPDH is a multi-functional enzyme that is well-known to be sensitive to redox
status (Brandes et al., 2009; Chernorizov et al., 2010).

We hypothesized that the

increased glutathione (GSH) levels in S47 cells (Leu et al., 2019) might alter the redox
state of GAPDH and impact its ability to bind to Rheb. We first verified that lung tissue
and skeletal muscle from S47 mice possess increased GSH compared to WT tissues, as
assessed by an increased ratio of reduced versus oxidized glutathione (GSH:GSSG)
(Figure 2.5A). We also validated that the GSH alkylating agent diethylmaleate (DEM)
could successfully decrease the level of GSH, and the GSH/GSSG ratio, in cells (Figure
2.5A); these findings are consistent with previously published findings by our group (Leu
et al., 2019). Notably, DEM treatment of immortalized S47 MEFs (iMEFs) caused a
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dramatic decrease in markers of mTOR activity (p-mTOR and p-S6K1), showing for the
first time that modulation of GSH, even for as little as five hours, can impact mTOR
activity. We found that the impact of DEM on mTOR activity was further enhanced by
the addition of glutamate (Figure 2.5B); glutamate decreases cystine import through
System Xc(-), leading to decreased level of GSH.
We next sought to test the hypothesis that the redox state of GAPDH was altered
in WT and S47 cells. Toward this end we employed cross-linking experiments using the
cysteinyl cross-linking agent bismaleimidohexane (BMH), which cross-links cysteine
residues within 13Å by covalently conjugating free (reduced) sulfhydryl groups (Green et
al., 2001). We treated freshly isolated lung and skeletal muscle lysates from WT and
S47 mice, and from immortalized WT and S47 MEFs (iMEFs), with BMH. Cysteinylcrosslinked proteins were resolved on SDS-PAGE gels and compared to untreated
extracts. Notably, we found consistent differences in GAPDH cross-linking patterns in
S47 samples compared to WT, as evidenced by altered mobility of GAPDH on SDSPAGE of BMH-treated samples (Figure 2.5C). This altered mobility of GAPDH in S47
cells could be reversed by glutathione depletion by DEM treatment (Figure 2.5C) and by
the compound BSO (buthionine sulfoximine; Supplemental Figure 2.5A), which inhibits
GSH biosynthesis. Treatment with the compound erastin, which inhibits the system Xc
(-) cystine transporter, also led to altered mobility of GAPDH in S47 and WT cells
(Supplemental Figure 2.5B).
We next tested the impact of modulating GSH on the interaction between Rheb
and GAPDH in WT and S47 cells using both IP-western and PLA. By IP-western we
found that supplementation of culture media with exogenous GSH decreased the RhebGAPDH interaction in WT cells; conversely, depleting free GSH using either BSO or
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DEM increased the Rheb-GAPDH interaction in S47 cells (Figure 2.5D). These findings
were corroborated using PLA, which revealed that depleting GSH in WT and S47 cells
using either DEM or BSO completely restores GAPDH-Rheb complex formation and
mTOR-Rheb complex formation in S47 cells, to levels equivalent to WT cells (Figure
2.5E and F; Supplemental Figure 2.5C). Our crosslinking experiments with BMH reveal
that there is an altered conformation of GAPDH in S47 cells in tissues, however the
exact change in conformation remains to be determined. In the future, it would be
worthwhile to perform glutaraldehyde crosslinking experiments to determine if
dimerization of GAPDH differs between WT and S47. The combined data support the
conclusion that the increased GSH pool in S47 cells affects the status of reactive
cysteines in GAPDH, and the ability of this protein to bind and sequester Rheb, thereby
leading to increased Rheb-mTOR interaction and increased mTOR activity in S47 cells.
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Figure 2.5: Increased glutathione drives decreased GAPDH-Rheb binding in S47 cells
(A) WT and S47 lung (left) and skeletal muscle (center) were assessed for GSH/GSSG ratio
(mean ± SD, n = 3). WT and S47 immortalized MEFs (iMEFs), either untreated or treated with 50
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μM DEM for 5 h, were analyzed for GSH/GSSG ratio (mean ± SD, n = 4). (B) WT and S47 iMEFs
were either untreated, treated with 50 μM of DEM or 50 μM of DEM + 0.5 mM glutamate for 5 h
and protein lysates were analyzed by Western blot for indicated mTOR markers. (C) Whole cell
lysates were extracted from WT and S47 mouse lung (left) and skeletal (center) tissue. Proteins
were cross-linked with BMH, resolved by SDS/PAGE, and detected by Western blotting with a
GAPDH specific antibody (Top).

Untreated protein lysates were analyzed by Western blot

analysis for total GAPDH (Bottom). WT and S47 iMEFs were treated with 50 μM of DEM for 5 h
and protein lysates were analyzed as described (right). (D) WT cells were treated with PBS or 3
mM GSH for 24 hours. S47 cells were treated with PBS for 24 hours, PBS for 5 hours, 100 μM
BSO for 24 hours, or 50 μM DEM for 5 hours. IP of the lysates with anti-Rheb followed by
Western analysis for associated GAPDH and Rheb (top panel). The same lysates were analyzed
by Western blotting for GAPDH and Rheb (bottom panel). (E-F) Proximity ligation analysis (PLA)
was performed in WT and S47 MEFs treated with 50 μM of DEM for 5 hours and analyzed as
described in Figure 2.4A-B.

2.3.4 Enhanced metabolic efficiency of S47 mice
mTOR is known to regulate body mass and muscle regeneration (Laplante and
Sabatini, 2012; Yoon, 2017). We therefore next assessed body weight and fat/lean
content in age-matched male mice of WT and S47 genotypes. We also tracked body
weight with age of multiple male and female sibling littermate mice of WT/WT, WT/S47
and S47/S47 genotypes in our colony. S47 mice showed significantly increased weight
with time, compared to WT/WT and WT/S47 sibling littermates (Supplemental Figure
2.6A). Body composition analysis using nuclear magnetic resonance revealed that S47
mice had significantly increased fat and lean content, compared to WT mice (Figure
2.6A; Supplemental Figure 2.6B). We next analyzed the metabolic activities of WT and
S47 mice using a comprehensive lab animal monitoring system (CLAMS) over the
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course of 48 hours. In this analysis, S47 mice showed comparable locomotor activity to
WT mice but reduced food intake, oxygen consumption and heat production (Figure
2.6B). These CLAMS data suggested that S47 mice might possess enhanced metabolic
efficiency compared to WT mice and prompted us to assess the response of WT and
S47 mice to exercise challenge.
We subjected WT and S47 mice to treadmill exercise with increasing intensity
over time. For this analysis we studied eight age-matched male mice of each genotype
during a 50-minute forced exercise at increasing speed and slope. During this time
course, oxygen consumption and serum metabolites were quantified. Consistent with
our CLAMs experiment, S47 mice started with lower basal VO2 and exhibited generally
lower VO2 for the work being performed; however, as they approached the final, most
strenuous point of the exercise, the VO2 values in WT and S47 converged, so the V02
range for S47 mice was significantly greater than WT mice (Figure 2.6C-E). Analysis of
serum metabolites and proteins before and after exercise revealed decreased lactate
dehydrogenase (LDH) levels in the sera of S47 mice, suggesting decreased muscle
damage in S47 mice compared to WT (Figure 2.6F). Moreover, prior to exercise, we
noted that Ki-67 staining in S47 skeletal muscle was consistently increased relative to
WT (Supplemental Figure 2.6C); the latter finding is suggestive of enhanced ability for
S47 muscle to regenerate.

There were no differences in p53 level or markers of

mitochondrial content in the skeletal muscle of WT and S47 mice (Supplemental Figure
2.6D and E), nor were there other differences in other serum metabolites between WT
and S47 mice (Supplemental Figure 2.6F). The combined data, like the CLAMS data,
point to increased metabolic efficiency in S47 mice relative to WT mice. To address this
further, we analyzed a small cohort of male WT and S47 mice on a continuous
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strenuous treadmill run. Although the numbers are small, we found that three out of four
WT mice failed to complete 60-minute strenuous run, while three out of four S47
successfully completed this run (Supplemental Figure 2.6G).

49

Figure 2.6: Increased size and improved metabolic efficiency in S47 mice.
(A) Nuclear magnetic resonance (NMR) studies revealed S47 mice have increased body weight,
increased fat content and increased lean content, n=7 WT mice, n=8 S47 mice. (***) p-value <
0.001, (****) p-value < 0.0001.

Bar graphs are presented as mean ± SD.

(B) Changes in

metabolic parameters for WT mice (blue) and S47 mice (red) were determined by using the
Comprehensive Lab Animal Monitoring System for 48 hours. Parameters assessed includes
oxygen consumption, carbon dioxide production, respiratory exchange rate, energy expenditure,
total food intake and locomotor activity. The data are representative of 5 six-week old male mice
per genotype and are normalized to total body weight. (C) WT and S47 mice (n = 6-7) were
subjected to a treadmill study of increasing intensity over time. Oxygen consumption (VO2) is
normalized to body mass. (D) Mean basal VO2 in WT and S47 mice. (E) VO2 range in WT and
S47 mice determined by subtracting the mean basal VO2 from the VO2 max, obtained during the
most strenuous point of exercise at the tail end of the treadmill study. (F) Lactate dehydrogenase
(LDH) levels measured in the serum of WT and S47 mice obtained before and after the treadmill
study. (*) p-value < 0.05, Student’s t-test.

2.4 Discussion

In this study, we report that cells and mice with the S47 variant of p53 have
increased mTOR activity and increased metabolic efficiency. The animals also display
increased mass and signs of superior fitness. Our data support the premise that the
enhanced mTOR activity is due, at least in part, to the higher levels of GSH in S47 cells
and tissues. The increased GSH results in impaired ability of the redox sensitive protein
GAPDH to bind to Rheb.

This leads to greater mTOR-Rheb binding, resulting in

increased mTOR activity in S47 cells and tissues. These data indicate that, along with
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pH (Walton et al., 2018), cellular redox status can also regulate mTOR activity, in a
manner controlled by p53. We show that oxidative metabolism in S47 cells is less
sensitive to mTOR inhibitors, thus tying these two phenotypes together; this is not
surprising, as a link between mTOR and a number of cellular metabolic processes is well
known (Morita et al., 2013; Schieke et al., 2006).
We see evidence for increased mTOR activity only in certain tissues of the S47
mouse, so the metabolic impact of this genetic variant appears to be somewhat tissue
restricted. At present we do not know if this tissue specificity is due to differences in
GSH level, or to altered mTOR-Rheb or GAPDH-Rheb interactions in different tissues, or
to other parameters. We also see evidence for some unexpected findings regarding the
increase in mTOR activity in S47 cells: given that mTOR negatively regulates autophagy
(Jung et al., 2010), we expected to see differences in steady state autophagy or
autophagic flux in WT and S47 cells, but we found no evidence for this. This finding may
be due to the rather complex relationship between mTOR and autophagy (Jung et al.,
2010; White et al., 2011), and/or that other signaling pathways regulate autophagy aside
from mTOR, including the PI3K pathway, GTPases, and calcium (Yang et al., 2005). It
is also interesting to note that S47 cells exhibit increased use of the pentose phosphate
pathway and generate more NADPH compared to WT cells. Our collaborators have
observed decreased GAPDH activity, and an increase in G6PD activity, the rate limiting
enzyme in the pentose phosphate pathway (Leu et al., 2020). Thus, changes in NADPH
levels can also account for some of the redox differences observed in S47.
The increased lean content in S47 mice likely contributes to the increased fitness
observed in these mice. Human studies have shown that mTOR activation is crucial for
human muscle protein synthesis (Dickinson and Rasmussen, 2011). Treatment with the
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well-studied mTOR inhibitor rapamycin blocks the effects of amino acid ingestion on
mTOR activity and leads to decreased protein synthesis in human skeletal muscle
(Dickinson and Rasmussen, 2011; Drummond et al., 2009).

Additionally, mTOR

signaling driven through IGF-1 plays a key role in promoting muscle hypertrophy
(Coleman et al., 1995; Musaro et al., 2001; Vandenburgh et al., 1991). One caveat of
this study, however, is that we do not directly demonstrate that the increased mTOR
activity in S47 mice is causing their increased lean content or superior performance on
treadmill assays. Transient treatment with mTOR inhibitors elicits highly complex and
often contrasting effects on energy expenditure and treadmill performance, likely due to
the existence of feedback loops and the effect of inhibitors on multiple organ systems in
the mouse. As just two examples: rapamycin has shown contrasting effects on energy
expenditure in animals, depending on how long mice are treated (Fang et al., 2013);
similarly, treatment of mice with rapamycin has shown limited impact on treadmill
endurance, despite causing decreased expression of genes involved in mitochondrial
biogenesis and oxidative phosphorylation in the muscle (Ye et al., 2013). Possibly the
most consistent findings in the literature reflect the general consensus that mTORC1 is
involved in mechanisms that drive increased muscle mass (Goodman, 2019) and that
heightened mTOR activity leads to enhanced muscle recovery after exercise (Song et
al., 2017; Yoon, 2017). It remains to be tested if these are the pathways affected in S47
mice.
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Figure 2.7: Proposed model of how S47 contributes to increased metabolism
(A) The elevated levels of GSH alter the redox state of the S47 cell, in turn affecting GAPDH
conformation and impairing GAPDH-Rheb binding.

This results in increased mTOR-Rheb

binding, leading to increased mTOR activity and resulting an overall increase in metabolism in
S47 mice, as seen by increased fat and lean content. (B) Broad impact of S47 variant: though
providing an adaptive advantage to individuals residing in sub-Saharan Africa at one point in time,
it now predisposes modern humans with this SNP to cancer.

We hypothesize that the more efficient metabolism and enhanced fitness
provided by the S47 variant may have once provided carriers with a bio-energetic
advantage in Sub-Saharan western Africa, where this variant is most common. For
example, those carrying the S47 SNP may have possessed superior athletic prowess
and/or ability to withstand famine (see model, Figure 2.7). This metabolic advantage
may explain the high frequency of this genetic variant in sub-Saharan Africa, despite the
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fact that it predisposes individuals to cancer later in life. A selection for this variant in
Africa may also include an improved ability to withstand malaria infection: we recently
reported that the S47 variant alters the immune micro-environment in mice and confers
improved response to the malaria toxin hemozoin (Singh et al., 2020). Both of these
activities may have conferred selection pressure for this variant in Africa.
Our findings provide further support for the growing premise that some tumor
suppressor genetic variants may provide evolutionary selection benefit (Vicens and
Posada, 2018).

For example, women who carry the BRCA1/2 mutation exhibit

increased size and enhanced fertility when compared to controls (Smith et al., 2012).
Similarly, people with Li Fraumeni syndrome who inherit germline mutations in TP53, as
well as mice with tumor-derived germline mutations in Tp53, demonstrate increased
fitness endurance (Wang et al., 2013); however, this is due to increased mitochondrial
content, which we do not see in S47 cells. A common genetic variant in TP53 at codon
72, encoding proline at amino acid 72, confers increased longevity while conversely
causing increased cancer risk (Zhao et al., 2018). In contrast, the arginine 72 variant of
p53 induces increased expression of LIF, which improves fecundity (Kang et al., 2009).
The take home message from all of these studies is that the diverse roles of tumor
suppressor proteins like p53 in metabolism, fertility and fitness may allow for positive
selection for certain variants, even at the expense of increased cancer risk. In mice, this
increased cancer risk occurs quite late in life, well past reproductive selection (12-18
months).

More needs to be done to analyze cancer risk in S47 humans. A more

comprehensive understanding of the function of tumor suppressor genetic variants,
including the S47 SNP, will enable improved understanding of cancer risk, along with
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superior personalized medicine approaches, with the ultimate goal of improving clinical
outcomes and survival of people who carry this variant.

2.5 Materials and Methods
2.5.1 Mammalian cell culture
WT and S47 MEFs were generated and maintained as previously described (Jennis et
al., 2016). Human WT LCLs (Catalog ID GM18870) and S47 LCLs (Catalog ID
GM18871) were obtained from the Coriell Institute (Camden, New Jersey) and
maintained as previously described (Jennis et al., 2016). MEF cultured cells were grown
in DMEM (Corning Cellgro) supplemented with 10% fetal bovine serum (HyClone, GE
Healthcare Life Sciences) and 1% penicillin/streptomycin (Corning Cellgro).

Human

LCLs were grown in RPMI (Corning Cellgro) supplemented with 15% heat inactivated
fetal

bovine

serum

(HyClone,

GE

penicillin/streptomycin (Corning Cellgro).
incubator at 37°C.

Healthcare

Life

Sciences)

and

1%

Cells were grown in a 5% CO2 humidified

For serum starvation experiments, cells were starved in DMEM

containing 0.1% FBS for 16 hours. Following starvation, DMEM containing 10% FBS
was re-introduced and cells were harvested at 0 minutes, 10 minutes, 30 minutes, 1
hour, 2 hours and 8 hours after this point. For glucose starvation experiments, cells
were starved in glucose-free DMEM (Thermo Fisher Scientific 11966025) for 16 hours.
Following starvation, DMEM containing 4.5 g/L glucose was re-introduced and cells were
harvested at 0 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours and 5 hours after this
point. For amino acid starvation experiments, cells were starved for 4 hours in EBSS
(Thermo Fisher Scientific 24010043) containing 25 mM glucose, 0.5 mM Glutamine, 1X
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MEM Vitamin (Thermo Fisher Scientific 11120052), 0.2% FBS, 25 mM HEPES, 1X
Penicillin/Streptomycin. Following starvation, the same media recipe now containing 1X
MEM Amino Acids (Thermo Fisher 1130051) was re-introduced and cells were
harvested at 0 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours and 5 hours after this
point. For HBSS experiments, cells were washed once with PBS (Corning 21-031-CV)
and then incubated with HBSS (Thermo Fisher Scientific 14025092) for 0, 2 or 6 hours.
Viability was assessed using Trypan Blue (Thermo Fisher Scientific 15250061).

2.5.2 Western blot
For Western blot analyses, 50-100 µg of protein was resolved over SDS-PAGE gels
using 10% NuPAGE Bis-Tris precast gels (Life Technologies) and were then transferred
onto polyvinylidene difluoride membranes (IPVH00010, pore size: 0.45 mm; Millipore
Sigma).

Membranes were blocked for 1 hour in 5% bovine albumin serum (Sigma

Aldrich, A9647).

The following antibodies were used for Western blot analyses:

phospho-mTOR 1:1000 (Cell Signaling, 2971), mTOR 1:1000 (7C10, Cell Signaling,
2983), phospho-p70S6K1 1:1000 (Cell Signaling, 9205), p70S6K1 1:1000 (Cell
Signaling, 9202), GAPDH 1:10,000 (14C10, Cell Signaling, 2118), TFAM 1:2000
(Abcam, ab131607), MTCO1 1:2000 (Abcam, ab14705), SDHA 1:1000 (Cell Signaling,
5839), Tom20 1:100 (F-10, Santa Cruz, sc17764), phospho-Akt (D9E, Cell Signaling,
4060), p62 1:1000 (Cell Signaling, 5114), LC3B 1:1000 (D11, Cell Signaling, 3868),
HSP90 1:1000 (Cell Signaling, 4877S), Rheb 1:1000 (E1G1R, Cell Signaling, 13879),
TSC2 1:1000 (D93F12, Cell Signaling, 4308), Akt 1:1000 (Cell Signaling, 9272), Deptor
1:1000 (Novus Bio, NBP1-49674SS), phospho-AMPKα (Cell Signaling, 2535). Rabbit or
mouse secondary antibodies conjugated to horseradish peroxidase were used at a
1:10,000 dilution (Jackson Immunochemicals), followed by a 5-minute treatment with
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ECL (Amersham, RPN2232). Protein levels were detected using autoradiography and
densitometry analysis of protein content was conducted using ImageJ software (NIH,
Rockville, MD).

2.5.3 Immunohistochemistry
Tissues were harvested and fixed in formalin overnight at 4°C, followed by a wash with
1X PBS and were then placed in 70% ethanol prior to paraffin embedding. The Wistar
Institute Histotechnology Facility performed the tissue embedding and sectioning. For
the immunohistochemistry (IHC) studies, paraffin embedded tissue sections were deparaffinized in xylene (Fisher, X5-SK4) and re-hydrated in ethanol (100%-95%-85%75%) followed by distilled water.

Samples underwent antigen retrieval by steaming

slides in 10 mM Citrate Buffer (pH 6). Endogenous peroxidase activity was quenched
with 3% hydrogen peroxide and slides were incubated in blocking buffer (Vector
Laboratories, S-2012) for 1 hr.

The slides were incubated with phospho-p70S6K1

(1:100, ThermoFisher Scientific, PA5-37733) or phospho-mTOR (1:100, Cell Signaling,
2971) primary antibody overnight at 4°C. The following day, slides were washed with
PBS and incubated with HRP-conjugated secondary antibody for 30 mins. Antibody
complexes were detected using DAB chromogen (D5637). Light counterstaining was
done with hematoxylin. Slides were imaged using the Nikon 80i upright microscope and
at least four fields were taken per section.

2.5.4 Co-Immunoprecipitation
Following overnight seeding of WT and S47 immortalized MEFs, the cells were washed
with 1X DPBS and the cell culture medium was replaced with 1% FBS DMEM medium
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[pyruvate-free DMEM (Thermo Fisher Scientific #21013024) supplemented with 1%
FBS, 1% penicillin/streptomycin, 0.1 mM L-Methionine, 0.5 mM L-Glutamine, and 0.033
mM L-Cystine]. WT cells were treated with PBS or 3 mM GSH for 24 h; while the S47
cells were treated with PBS for 5 h or 24 h, 100 μM BSO for 24 h, or 50 μM DEM for 5 h.
Cells were harvested and centrifuged at 500 x g for 10 min at 4°C. The cell pellets were
resuspended in CHAPS Lysis Buffer (1X DPBS with 0.3% CHAPS and freshly added
protease inhibitors) at 4˚C. Cell disruption was performed by passing the cells through a
23-gauge needle attached to a 1 ml syringe. The skeletal muscles were homogenized
using the Qiagen Tissue Lyser II. Total cellular homogenates were rotated/nutated at
4°C for 30 min, and spun at 11,000 x g for 20 min at 4°C. Protein extracts (3 mg per
reaction) were incubated with the Rheb antibody (Santa Cruz, sc-271509) overnight at
4˚C. The Rheb-immunocomplexes were captured using recombinant protein G agarose
(Thermo Fisher Scientific, 15920010) at 4˚C for 2 h. Resins were washed three times
using the CHAPS Lysis Buffer.

Equal volumes of 2x Laemmli Sample Buffer were

added to each reaction, samples were heated for 10 min at 100°C.

The Rheb-

associated proteins were analyzed by Western blotting, using GAPDH (Cell Signaling,
2118), Rheb (Cell Signaling, 13879) and mTOR (7C10, Cell Signaling, 2983) antibodies.

2.5.5 Mitochondrial metabolism and mTOR inhibition assays
The oxygen consumption rate (OCR) and glycolytic rate were determined using the
Seahorse XF MitoStress Assay and the Seahorse XF Glycolytic Rate Assay,
respectively, according to the manufacturer’s protocol. Cells were plated one day prior
to the assay, LCLs at 100,000 cells/well and MEFs at 60,000 cells/well. LCLs were
treated with 200 nM rapamycin, 100 nM Torin1 or 1 μM Torin1 for 24 hours prior to
running the MitoStress Assay. To assess differences in mTOR inhibition, WT and S47
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LCLs were treated with 200 nM rapamycin or 100 nM Torin1 for 0 minutes, 10 minutes,
30 minutes, 1 hour, 2 hours, or 6 hours and subsequently cells were harvested for
Western blot analysis. To determine mitochondrial content, WT and S47 MEFs were
incubated with 500 nM of MitoTracker Green (ThermoFisher Scientific, M7514) for one
hour at 37°C. Cells were then spun down, washed once with PBS, spun down and
resuspended in PBS. The FACSCelesta (BD Biosciences) was used to detect
fluorescence and at least 10,000 events were measured per sample.

2.5.6 Metabolite measurements
Media was collected after 24 hours after plating LCLs or MEFs, and the YSI-71000
Bioanalyzer was used to determine glucose, glutamine, lactate and glutamate levels as
previously described (Londono Gentile et al., 2013). For the metabolic flux studies, cells
were incubated in uniformly labeled

13

C-glucose (25 mM) as indicated in the figure

legends. For intracellular extracts, after incubation, the culture medium was aspirated,
and cells were washed once in ice-cold PBS. Metabolites were extracted by adding a
solution of methanol/acetonitrile/water (5:3:2) to the well. Plates were incubated at 4oC
for 5 minutes on a rocker and then the extraction solution was collected. The metabolite
extract was cleared by centrifuging at 15,000 x g for 10 minutes at 4oC. Supernatants
were transferred to LC-MS silanized glass vials with PTFE caps and either run
immediately on the LC-MS or stored at -80oC. LC-MS analysis was performed on a Q
Exactive Hybrid Quadrupole-Orbitrap HF-X MS (ThermoFisher Scientific) equipped with
a HESI II probe and coupled to a Vanquish Horizon UHPLC system (ThermoFisher
Scientific). 0.002 ml of sample is injected and separated by HILIC chromatography on a
ZIC-pHILIC 2.1-mm.

Samples were separated by ammonium carbonate, 0.1%

ammonium hydroxide, pH 9.2, and mobile phase B is acetonitrile. The LC was run at a
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flow rate of 0.2 ml/min and the gradient used was as follows: 0 min, 85% B; 2 min, 85%
B; 17 min, 20% B; 17.1 min, 85% B; and 26 min, 85% B. The column was maintained at
45oC and the mobile phase was also pre-heated at 45oC before flowing into the column.
The relevant MS parameters were as listed: sheath gas, 40; auxiliary gas, 10; sweep
gas, 1; auxiliary gas heater temperature, 350oC; spray voltage, 3.5 kV for the positive
mode and 3.2 kV for the negative mode. Capillary temperature was set at 325oC, and
funnel RF level at 40. Samples were analyzed in full MS scan with polarity switching at
scan range 65 to 975 m/z; 120,000 resolution; automated gain control (AGC) target of
1E6; and maximum injection time (max IT) of 100 milliseconds.

Identification and

quantitation of metabolites was performed using an annotated compound library and
TraceFinder 4.1 software. The “M+X” nomenclature refers to the isotopolog for that
given metabolite. Isotopologs are chemically identical metabolites that differ only in their
number of carbon-13 atoms. For instance, “M+2 citrate” means that two of the six
carbons in citrate are carbon-13 while the other four are carbon-12. “M+4 citrate” means
that four of the six carbons in citrate are carbon-13 while the other two are carbon-12.

2.5.7 GSH/GSSG abundance and BMH crosslinking
Relative GSH/GSSG abundance was measured using the GSH/GSSG-Glo Assay
(Promega catalog #V6611, according to the manufacturer’s instruction. Immortalized
WT and S47 MEFs were generated and maintained as previously described (Jennis et
al., 2016; Leu et al., 2019). For BMH crosslinking studies, the WT and S47 cells were
cultured in 1% FBS DMEM medium and treated with PBS or 50 μM diethyl maleate
(DEM, ThermoFisher Scientific AC114440010) for 5 h; PBS or 100 μM BSO (Cayman
Chemical item #14484) for 24 h; or DMSO or 2 μM Erastin (Cayman Chemical item
#17754) for 24 h. Proteins were extracted from cultured cells or mouse tissue (skeletal
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muscle, lungs) using 1X DPBS (Thermo Fisher Scientific 14190144) supplemented with
0.5% IGEPAL CA-630, 1 mM PMSF, 6 μg/ml aprotinin, and 6 μg/ml leupeptin at 4˚C.
The tissues were homogenized using the Wheaton Overhead Stirrer.

Total cellular

homogenates were pulse sonicated using the Branson digital sonifier set at 39%
amplitude. Total protein extracts (100 μg per reaction) were incubated with or without 1
mM BMH (Thermo Fisher Scientific 22330) for 30 min at 30°C. The samples were
quenched with an equal volume of 2x Laemmli Sample Buffer (BioRad 1610737)
supplemented with 5% β-Mercaptoethanol (BioRad 1610710) and heated for 10 min at
100°C. The protein samples were size fractionated on Novex 4-20% Tris-Glycine Mini
Gels (Thermo Fisher Scientific XP04200BOX) at room temperature and subsequently
transferred overnight onto Immuno-Blot PVDF membranes (BioRad 1620177) at 4˚C.
The membranes were blocked with 3% nonfat dry milk (BioRad 1706404) in 1X PBST
for 30 min at room temperature and incubated with the GAPDH antibody (Cell Signaling
Technology 2118) overnight with rotation/nutation at 4˚C. After washing the blots in 1X
PBST,

the

membranes

were

incubated

with

Donkey

anti-Rabbit

(Jackson

ImmunoResearch 711-036-152) for 2 h at room temperature. Membrane-immobilized
protein detection used ECL Western blotting Detection Reagents (GE Healthcare
RPN2106; Millipore Sigma GERPN2106).

2.5.8 Proximity Ligation Assay
Cells were grown on Lab-Tek II 8-well chamber slides, and were either untreated,
treated with 50 μM diethyl maleate (DEM, ThermoFisher Scientific AC114440010) for 5
hours or treated with 10 μM of buthionine sulfoximine for 24 hours (BSO, Cayman
Chemicals, 83730-53-4) and fixed with 4% paraformaldehyde (Electron Microscopy
Sciences, 15710). Protein-protein interactions were assessed using the PLA Duolink in
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situ starter kit (Sigma Aldrich, DUO92101) following the manufacturer’s protocol. The
following primary antibodies were used: Rheb 1:50 (B-12, Santa Cruz, sc271509),
mTOR 1:500 (7C10, Cell Signaling, 2983), GAPDH 1:1000 (14C10, Cell Signaling,
2118). ImageJ software (NIH, Rockville, MD) was used to quantify PLA signals.

2.5.9 Immunofluorescence staining
Cells were fixed in 4% paraformaldehyde for 10 minutes, followed by 3 PBS washes and
then permeabilization with 0.25% Triton X-100 for 10 minutes. Cells were washed 3x
with PBS, blocked for 1 hour in a PBS solution containing 1% bovine serum albumin and
5% normal goat serum (Jackson Immunoresearch 005-000-121). Cells were incubated
overnight at 4ºC with the following primary antibodies diluted in blocking buffer: Rheb
1:800 (Cell Signaling Technologies, #13879), TSC2 1:100 (Cell Signaling Technologies,
#4308), LAMP1 1:50 (Santa Cruz, sc-20011). Cells were washed with PBS and
incubated with the following secondary antibodies at 37 ºC for 45 minutes: Alexa Fluor
594 AffiniPure Goat Anti-Rabbit IgG (Jackson Immunoresearch 111-585-144) and Alexa
Fluor 488 AffiniPure Goat Anti-Mouse IgG (Jackson Immunoresearch 115-545-062). The
cells were mounted with media containing DAPI and images were captured using the
Leica TSC SP5 microscope.

2.5.10 Body composition and metabolic cage studies
WT and S47 mice in a pure C57Bl/6 background are previously described (Jennis et al.,
2016). All mouse studies were performed in accordance with the guidelines in the Guide
for the Care and Use of Laboratory Animals of the NIH and all protocols were approved
by the Wistar Institute Institutional Animal Care and Use Committee (IACUC). Mice
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were fed an ad libitum diet and were housed in plastic cages with a 12-hour/12-hour light
cycle at 22°C unless otherwise stated. Fat and lean content were measured in live male
mice at 6 weeks of age using nuclear magnetic resonance (NMR) with the Minispec
LF90 (Bruker Biospin, Billerica, MA).

Indirect calorimetry was conducted to assess

metabolic capabilities in mice (Oxyman/Comprehensive Laboratory Animal Monitoring
System (CLAMS); Columbus Instruments).

Data for the WT mice was previously

published in supplemental data of Kung et al., 2016. Six-week old mice were single
caged, provided with water and food ad libitum and allowed to acclimate to the cages for
2 days. Oxygen consumption (VO2) and carbon dioxide production (VCO2) were
recorded for 48 hours using an air flow of 600 ml/min and temperature of 22°C.
Respiratory exchange ratio (RER) is calculated as VCO2/VO2 and heat (kcal/h) is
calculated by 3.815 + 1.232*(RER). Photodetectors were used to measure physical
activity (Optovarimex System; Columbus Instruments).

2.5.11 Treadmill and serum metabolite studies
Mice were allowed to acclimate to the metabolic treadmill (Columbus Instruments) for 5
minutes before beginning their runs. The treadmill was then set to 5m/min and speed
increased by 5m/min every 2 minutes until 20m/min was reached. Upon reaching 20
m/min, the incline was increased by 5 degrees every 2 minutes until reaching a
maximum of 25 degrees. Mice were allowed to run at this maximum speed and incline
until exhaustion, defined by the mice spending 10 continuous seconds on the shock grid.
Lactate (Nova Biomedical) and glucose (One Touch) measurements were taken using
test strips just prior to treadmill entry and immediately after exhaustion using handheld
meters.

Tail blood was also taken prior to treadmill entry and immediately after
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exhaustion and metabolites measured using the Vettest serum analyzer (Idexx
Laboratories).

2.5.12 Statistical Analysis
Unless otherwise stated, all experiments were performed in triplicate. The two-tailed
unpaired Student t-test was performed. All in vitro data are reported as the mean ± SD
unless stated otherwise, and in vivo are reported as the mean ± SE. Statistical analyses
were performed using GraphPad Prism, p-values are as follows: (*) p-value < 0.05, (**)
p-value < 0.01, (***) p-value < 0.001, (****) p-value < 0.0001. For the CLAMs and mouse
exercise data, the Wilcoxon rank-sum test was used to compare the differences between
S47 and WT mice.
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2.6 Supplemental Figures

Supplemental Figure 2.1: Altered metabolic markers in S47 cells and tissues.
(A) Microarray analysis of WT and S47 LCLs treated with 10 μM cisplatin for 0, 8 & 24 hours
reveal several metabolism genes as differentially expressed. * regulators of mTOR (B) qRT-PCR
analysis of PRKAB1, SESN1 and PTEN in human LCLs treated with 10 µM cisplatin for 24 hours.
All values were normalized to a control gene (18S); n=4, error bars indicate standard deviation.
(*) p-value < 0.05, (**) p-value < 0.01, (***) p-value < 0.001, (****) p-value < 0.0001, Student’s t-
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test. (C) Whole cell lysates were extracted from WT and S47 liver, lung, heart and kidney
followed by Western blot analysis for the proteins indicated. (D) Whole cell lysates were extracted
from 3 WT and 3 S47 mouse lungs and analyzed by Western blot for the phospho-Akt and
GAPDH (loading control). Light and dark exposures are shown. (E) WT and S47 MEFs were
starved in amino acid free media for 4 hours, then media containing amino acids was reintroduced and samples were collected at indicated time points. Cell lysates were extracted from
samples and subjected to Western blot analysis for the proteins indicated. (F) Densitometry
quantification of phospho-S6K1 protein expression in WT and S47 MEFs at one-hour time point
for serum and glucose starvation, 30-minute time point for amino acid starvation; all values
normalized to total S6K1. Densitometry values are averaged from a minimum of two independent
experiments. (G) Whole cell lysates were extracted from WT and S47 mouse lung and skeletal
tissue and were subjected to Western blot analysis, probing for p62, LC3B and HSP90 (loading
control). (H) WT and S47 MEFs were treated with HBSS for 0, 2 and 6 hours and were subjected
to Western blot analysis for the indicated proteins. (I) Autophagic flux was measured in WT and
S47 MEFs pretreated with NH4Cl for indicated time points, followed by HBSS treatment for 6
hours. Cell lysates were subjected to Western blot analysis and immunoblotted for LC3B and
GAPDH (loading control). (J) WT and S47 MEFs were treated with HBSS for indicated time points
and were subjected to viability analysis using Trypan Blue; n = 3, error bars indicate standard
deviation.
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Supplemental Figure 2.2:

Increased metabolism in S47 MEFs but no differences in

mitochondrial content in WT and S47 cells.
(A-D) WT and S47 MEFs were incubated with 25 mM

13

C-glucose for 15 minutes and the

abundance of citrate (A), malate (B), aspartate (C) and glutamate (D) isotopologs was quantified
by LC-MS/MS. Data are presented as mean ± SD, n =3; 2-way ANOVA. (*) p-value < 0.05, (**)
p-value < 0.01, (***) p-value < 0.001, (****) p-value < 0.0001. (E) Mitochondrial mass in WT and
S47 MEFs measured by Mitotracker Green fluorescence. Data depicted are representative of
three independent experiments performed in triplicate.
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(F) Cell lysates extracted from WT,

WT/S47 (het) and S47 LCLs and WT and S47 homozygous MEFs were subjected to Western blot
analysis and immunoblotted for TFAM, MTCO1, SDHA, TOMM20 and GAPDH (loading control).

Supplemental Figure 2.3: Attenuated response to mTOR inhibition in S47 cells
(A) WT and S47 LCLs were treated with 200 nM of rapamycin, harvested at indicated time points
after treatment and analyzed for shown mTOR markers via Western blot. (B) OCR as measured
by the Seahorse XF Mito Stress Test in WT and S47 LCLs treated with 1 μM of Torin1 for 24
hours. Note that samples were run on the same plate as the data depicted in Figure 2.3C;
therefore, the untreated samples are identical to Figure 2.3C but are presented here for
comparison sake and clarity.
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Supplemental Figure 2.4: No differences in the level of mTOR regulators in WT and S47
cells
(A) Cell lysates were extracted from two sets of WT and S47 MEFs and were analyzed by
Western blot for TSC2, DEPTOR, AKT, p53, Sco2 and GAPDH. (B) Cell lysates were extracted
from WT and S47 MEFs treated with 10 μM Nutlin for indicated time points. TSC2, phosphoAMPKα and GAPDH were assessed by Western blot. (C) Mice were fasted for 24 hours and
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intraperitoneally injected with saline or glucose (2g/kg body weight). Whole cell lysates were
extracted from skeletal muscles at 1 hour post-injection and subjected to Western blot analysis
for GAPDH and Rheb (left). The same lysates were immunoprecipitated (IP) with Rheb antibody
followed by Western analysis for the level of associated GAPDH and Rheb (right). (D) WT and
S47 MEFs were untreated or treated with 50 μM of DEM for 5 h. Cell lysates were subjected to
Western blot analysis and immunoblotted for total mTOR, Rheb and GAPDH. (E) WT and S47
MEFs were immunostained with LAMP1 (Alexa488-green) and either TSC2 or Rheb (Alexa594red) to determine co-localization. Nuclei are visualized with DAPI staining. Scale bars represent
30 µM.
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Supplemental Figure 2.5: Glutathione depletion by BSO alters GAPDH cross-linking and
the GAPDH-Rheb interaction
(A) WT and S47 cells were treated with PBS or 100 μM BSO for 24 hours. Lysates were
prepared, treated with or without BMH, run on SDS-PAGE and detected by Western blotting with
a GAPDH antibody. (B) WT and S47 cells were treated with DMSO or 2 μM Erastin for 24 hours.
Lysates were prepared, treated with or without BMH, resolved by SDS-PAGE, and probed by
Western blotting for GAPDH. (C) An in situ proximity ligation assay was performed in WT and
S47 MEFs that are treated with 10 μM of BSO for 24 h. Shown on the right is the quantification of
the mTOR-Rheb interactions, measured as the average number of PLA signals per nuclei.
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Supplemental Figure 2.6: Serum metabolites and protein markers pre- and post- exercise.
(A) Record of mouse weights in WT, S47 and heterozygous WT/S47 mice over the course of 18
weeks; a minimum of 10 mice of each genotype were tracked, and error bars mark standard
error. (B) Body weight, fat content and lean content as measured by proton magnetic resonance
spectroscopy (H-MRS); n=5 mice per genotype, error bars mark standard error, (*) p-value <
0.05. (C) Ki67 immunohistochemical staining of skeletal muscle from WT and S47 mice. IgG
control shown on right. (D) Total p53 protein levels in WT and S47 lung and skeletal tissue. (E)
Whole cell lysates were extracted from gastrocnemius or soleus muscle from untreated WT and
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S47 mice and subjected to Western blot analysis for the proteins indicated. (F) Blood serum
metabolite levels measured in WT and S47 mice before and after treadmill run: Ca (calcium), ALB
(albumin), PHOS (phosphate), CK (creatine kinase), BUN (blood urea nitrogen), LAC (lupus
anticoagulant), TP (total protein). n.s. not significant, Student’s t-test. (G) WT and S47 mice
were subjected to a 60-minute treadmill run. Table indicates proportion of mice that completed
run; n = 4.
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Chapter 3: PLTP Identified as a p53-Target Gene that Mediates Ferroptosis
Resistance in HepG2 Cells

This chapter has been adapted from the following manuscript in preparation:
Gnanapradeepan K, Murphy ME. PLTP Identified as a p53-Target Gene that
Mediates Ferroptosis Resistance in Liver Cancer Cells. (in prep)
3.1 Abstract

The tumor suppressor protein p53 prevents oncogenesis through processes such as
apoptosis and cell cycle arrest, however recently its role in regulating ferroptotic cell
death has begun to emerge. Ferroptosis is driven by the inactivation of glutathione
peroxidase 4 (GPX4), a phospholipid peroxidase, leading to accumulation of lethal levels
of lipid peroxidation and ultimately resulting in cell death. How exactly p53 mediates
ferroptosis remains poorly understand, as it has been shown to play a role in both
inducing and suppressing ferroptosis based on the context. Here, we identified PLTP
(phospholipid transfer protein) as a direct p53 target gene that plays a role in mediating
ferroptosis resistance in HepG2 cells. We found that silencing PLTP expression
sensitized cells to RSL3-induced cell death and lipid peroxidation, while activation of
PLTP expression protected cells from RSL3-induced cell death and decreased lipid
peroxidation. Our data suggest that PLTP promotes lipid storage, sequestering lipids into
lipid droplets and away from the cell membrane, thus protecting lipids from peroxidation
at the membrane. Taken together, our findings reveal a novel role for p53 in driving
ferroptosis resistance and indicate lipid transport as another key pathway involved in the
regulation of ferroptosis.
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3.2 Introduction

The TP53 gene is the most frequently mutated gene in cancer and has a wellestablished role in tumor suppression. It encodes the protein p53, which most commonly
serves as a transcription factor that regulates hundreds of downstream target genes to
prevent tumorigenesis (Kastenhuber and Lowe, 2017). For decades, it was believed that
cell cycle arrest, senescence and apoptosis were the primary modes of tumor
suppression and in recent years many other p53 functions have begun to emerge such
as control of metabolism, autophagy, cellular redox state, and ROS control (Berkers et
al., 2013; Gnanapradeepan et al., 2018). It is clear that the context of p53 activation,
such as type of stress encountered or tissue in which this stress occurs, plays a vital role
in the type of response p53 subsequently elicits.
A mouse model with a defective acetylation site, known as the 3KR mouse, was
characterized as being impaired for cell cycle arrest, senescence and apoptosis, yet still
retained its ability to halt tumor formation (Li et al., 2012). This suggested that the
canonical functions of p53 are not solely responsible for tumor suppression. Upon further
investigation, it was revealed that these mice were protected from cancer because they
retained the ability to undergo ferroptosis. Ferroptosis is best described as an iron
mediated, caspase independent form of cell death driven through the peroxidation of
polyunsaturated fatty acids. It is a process that differs from other forms of cell death on a
genetic, biochemical and morphological level (Dixon et al., 2012). GPX4 is a key protein
that is inactivated in ferroptosis, as it normally functions to neutralize the harmful lipid
reactive oxygen species that build up at the cellular membrane. SLC7A11 is a gene that
encodes part of a cystine/glutamate antiporter, and when repressed leads to ferroptosis
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induction (Jiang et al., 2015). Two small molecule inhibitors that are commonly used to
induce ferroptosis in vitro are RSL3 and erastin, which function by inhibiting GPX4 and
SLC7A11, respectively (Stockwell et al., 2017).
Various lipid metabolism genes have been implicated in ferroptosis sensitivity, as
lipid peroxidation plays such a crucial role in this process. Acyl-CoA synthetase longchain family member 4 (ACSL4) has been shown to drive ferroptosis by converting free
fatty acids into fatty CoA esters that are required for ferroptosis (Doll et al., 2017; Yuan
et al., 2016). ALOX15 and ALOX12 are two p53 target genes that promote ferroptosis by
serving as a lipoxygenases, necessary for the peroxidation of the polyunsaturated fatty
acids (Chu et al., 2019; Ou et al., 2016). Recently, stearoyl-CoA desaturase 1 (SCD1)
was found to protect ovarian cancer cells from ferroptosis by catalyzing the rate-limiting
step in monosaturated fatty acid synthesis (Tesfay et al., 2019). As ferroptosis is a
relatively new field, the precise mechanisms of regulation are still be ironed out.
The exact role of p53 in ferroptosis is likely to be cell type and stimulus specific.
Initial studies highlighted the role of p53 in promoting ferroptosis sensitivity (Gao et al.,
2015; Jennis et al., 2016; Jiang et al., 2015; Ou et al., 2016). However, other studies
have suggested that p53 stabilization can negatively regulate ferroptosis through
expression of CDKN1A/p21 (Tarangelo et al., 2018). In colorectal cancer cells, it was
found that p53 inhibits ferroptosis by blocking dipeptidyl-peptidase-4 (DPP4) activity (Xie
et al., 2017). Thus, further investigation is required in order to dissect the pleiotropic
functions of p53 in the control of ferroptosis.
Our lab generated a mouse model with a single nucleotide polymorphism at
amino acid 47 in TP53, hereafter referred to as the S47 mouse, and discovered it had
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impaired tumor suppressive function and a defect in ability to undergo ferroptosis (Jennis
et al., 2016). Using S47 as a tool, we have identified phospholipid transfer protein
(PLTP) as a novel p53 target gene that plays a role in mediating ferroptosis resistance in
HepG2 cells. PLTP is a lipid transport protein secreted predominantly from the liver and
plays a role in the transfer of various lipid molecules such as phosphatidylcholine,
phosphatidylethanolamine and phosphatidylglycerol to name a few (Albers et al., 2012).
Our findings characterize the function of PLTP in a p53 dependent context for the first
time and suggest a novel role for p53 in regulating ferroptosis through lipid transport.

3.3 Results
3.3.1 PLTP identified as gene that is downregulated by the S47 variant of p53
We have previously shown that the S47 variant of p53 is resistant to ferroptosis
induction, in part through decreased ability to repress SLC7A11 and transactivate GLS2
(Jennis 2016). Thus, we sought to use S47 as a tool to identify novel p53 target genes
that could play a role in mediating ferroptosis. To address this, human lymphoblastoid
cells (LCLs) homozygous for the S47 variant or WT p53 were jointly treated with the
ferroptosis inducers Nutlin plus tert-Butyl-hydroperoxide (TBH). TBH is widely used to
induce ROS and the combination of Nutlin and TBH has been used as a method of
ferroptotic induction (Ou et al., 2016). We focused our initial studies on the Nutlin/TBH
combination as we have found the LCLs used in our studies appear to be resistant to
erastin. RSL3 was found to be too cytotoxic on this cell type and results in a very low
yield of RNA. The RNA obtained from these samples was subjected to RNA sequencing,
which revealed PLTP as the top gene that was differentially expressed between WT and
S47 cells (Table 3.1, Figure 3.1A). To validate these findings, we performed qRT-PCR in
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LCLs that were either treated with Nutlin, TBH, or the combination of Nutlin and TBH,
and found that PLTP was significantly downregulated in S47 LCLs under all tested
conditions (Figure 3.1B). This was further confirmed by a similar qRT-PCR in WT and
S47 mouse embryonic fibroblasts (MEFs), which showed Pltp is also downregulated in
the mouse S47 cells (Figure 3.1C). Western blot analyses revealed that the protein
levels of PLTP are significantly lower in S47 LCLs (Figure 3.1D). In order to determine if
there was a difference in localization of PLTP in mouse tissue, IHC analyses were
conducted on liver tissue extracted from WT and S47 mice. It was found that PLTP is a
secreted protein that exists mostly in the extracellular space and appears to be present
at much lower levels in S47 liver tissue (Figure 3.1E). These collective data demonstrate
that PLTP is expressed at much lower levels in S47.
Table 3.1: Genes identified as being at least 3-fold downregulated in S47 LCLs

Gene

Function

PLTP

Transfers phospholipids from triglyceride-rich lipoproteins to high
density lipoprotein (HDL)

ASPA

Catalyzes conversion of N-Acetyl_L-aspartic acid to aspartate
and acetate

RBPMS2

Involved in development and dedifferentiation of digestive
smooth muscle cells

STRA6

Membrane protein that acts as receptor for retinol/retinol binding
protein complexes

EPS8L2

Links growth factor stimulation to actin organization

DUSP14

Dephosphorylates tyrosine and serine/threonine residues

CD6

Encodes protein found on outer membrane of Tlymphocytes/other immune cells; plays role in continuation of Tcell activation
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Figure 3.1: PLTP is differentially regulated by WT p53 and the S47 variant
(A) RNA-Seq identifying genes with significantly different expression between WT and S47 LCLs
treated with 5 µM Nutlin and 25 µM TBH for 0, 8 and 24 hours. Blue indicates decrease in gene
expression relative to untreated WT, red indicates increase. P-value <0.05 (unpaired t-test) and
FDR <25%. (B) qRT-PCR analysis of PLTP in LCLs treated with 5 µM Nutlin, 25 µM TBH or
combination of both, for 24 hours. All values were normalized to a control gene (18S); n=3, error
bars indicate standard error. (***) p-value < 0.001, Student’s t-test. (C) qRT-PCR analysis of Pltp
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in MEFs treated with 10 µM Nutlin and 25 µM TBH for 24 hours. All values were normalized to a
control gene (Cyclophilin A); n=3, error bars indicate standard error. (*) p-value < 0.05, Student’s
t-test. (D) Western blot analyses comparing PLTP expression in WT and S47 LCLs treated with 5
µM Nutlin, 25 µM TBH or combination of both, for 24 hours. (E) Immunohistochemical analysis of
PLTP in WT and S47 liver tissue. Data are representative of n = 4 fields per genotype. Scale bar
represents 100 μm.

3.3.2 The role of p53 in regulating PLTP and ferroptosis in HepG2 cells
The PLTP protein is secreted predominantly from the liver thus we focused our
studies on the HepG2 cancer cell line, which is derived from liver and expresses WT
p53. To ensure that PLTP is activated in a p53 dependent manner, we silenced p53 in
HepG2 cells using a short hairpin RNA. Nutlin was used to activate p53, and PLTP gene
expression was found to be significantly lower in the cells that were silenced for p53
(Figure 3.2A). We next treated our cells with Nutlin over a time course and found that
PLTP protein levels were again significantly lower in the sh-p53 cell line (Figure 3.2B).
Our data are consistent with previously reported findings, suggesting that PLTP is a
direct transcriptional target of p53 (Goldstein et al., 2012).
Before directly assessing the role of PLTP in ferroptosis, we wanted to assess
the sensitivity of HepG2 cells to ferroptosis, as it has been reported that different cell
lines express differential sensitivity to ferroptosis (Doll et al., 2017; Yuan et al., 2016).
Both erastin and RSL3 were capable of inducing ferroptosis in HepG2 cells, however
RSL3 was found to be a more potent inducer thus was used for the remainder of the
studies (Figure 3.2C-D). We compared the effects of silencing p53 on ferroptosis in
HepG2 cells and were surprised to detect no significant differences in ferroptosis
sensitivity between the silenced p53 cell line and control (Figure 3.2C-D). Recent studies
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have emerged suggesting that cell media and metabolism can influence ferroptosis
sensitivity in a p53 dependent manner (Leu et al., 2019; Tarangelo et al., 2018), so we
repeated this assay under low glucose and low serum media conditions. As expected,
these conditions further sensitized cells to ferroptosis using both erastin and RSL3, and
surprisingly, p53 silenced cells showed greater susceptibility to ferroptosis (Figure 3.2EF). Taken together, our data suggest that p53 plays a key role in regulating PLTP and
that in HepG2 cells, p53 negatively regulates ferroptosis.

Figure 3.2: p53 positively regulates PLTP but negatively regulates ferroptosis in HepG2
cells
(A) qRT-PCR analysis of PLTP in HepG2 cells treated with 10 µM Nutlin for 24 hours, with and
without p53 knockdown. All values were normalized to a control gene (18S); n=3, error bars
indicate standard error.

(***) p-value < 0.001, Student’s t-test. (B) Western blot analyses
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comparing PLTP expression in HepG2 cells with and without p53 knockdown. Cells were treated
with 10 µM Nutlin and lysates were harvested at 0 hr, 30 minutes, 24 hrs and 48 hrs. Data
representative of 3 independent experiments. (C-D) Viability analysis of HepG2 cells with and
without p53 knockdown treated with indicated doses of (c) erastin or (d) RSL3 for 72 hours in
complete media. Error bars represent standard error of mean, n=4. (E-F) Viability analysis of
HepG2 cells with and without p53 knockdown treated with indicated doses of (e) erastin or (f)
RSL3 for 72 hours in low glucose low serum media. Error bars represent standard error of mean,
n=4.

3.3.3 PLTP promotes ferroptosis resistance
Knowing that S47 cells are impaired in ferroptosis prompted us to assess the role
PLTP might play in ferroptosis. Two knockdown cell lines were generated using short
hairpins for PLTP in HepG2 and qRT-PCR confirmed that PLTP was effectively silenced
(Figure 3.3A). Knockdown of PLTP using two different short hairpins sensitized cells to
RSL3 induced cell death (Figure 3.3B and C). We next examined the effects of PLTP
silencing on the generation of lipid ROS, as lipid peroxidation is a key hallmark of
ferroptosis. Consistent with our viability data, we found that silencing PLTP significantly
increased lipid peroxidation that occurs after treatment with RSL3 (Figure 3.3D-E).
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Figure 3.3: Knockdown of PLTP increases RSL3-induced ferroptosis sensitivity.
(A) qRT-PCR analysis of PLTP expression in indicated knockdown HepG2 cells. All values were
normalized to a control gene (18S); n=3, error bars indicate standard error. (***) p-value < 0.001,
Student’s t-test. (B) Viability analysis of short hairpin control or PLTP knockdown cells treated
with indicated doses of RSL3 for 72 hours. Data are representative of three independent
experiments, four technical replicates, error bars represent standard error of mean. (C) Viability
analysis of short hairpin control or PLTP knockdown cells treated 0.1 µM RSL3 for 72 hours
(single point from b). Error bars represent standard deviation, (****) p-value < 0.0001, Student’s ttest. (D) Lipid peroxidation in knockdown cell lines treated with 0.5 µM RSL3 for 3 hours was
assessed by flow cytometry using C11-BODIPY. Data are representative of three independent
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experiments. (E) Quantification of lipid peroxidation levels. Error bars indicate standard deviation.
n=3, (**) p-value < 0.01

To extend these findings, we examined the effect of overexpressing PLTP in
HepG2 cells. Once the expression was confirmed via qRT-PCR (Figure 3.4A), we
proceeded to assess cell viability after RSL3 treatment. We found that PLTP
overexpression leads to ferroptosis resistance in cells treated with Nutlin and RSL3
(Figure 3.4B-C). Overexpression of PLTP significantly decreased RSL3 induced lipid
peroxidation (Figure 3.4D-E). The combined data support the premise that PLTP
expression drives ferroptosis resistance in HepG2 cells.
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Figure 3.4: Overexpression of PLTP confers ferroptosis resistance.
(A) qRT-PCR analysis of PLTP expression HepG2 cells containing empty vector and PLTP
cDNA. All values were normalized to a control gene (18S); n=3, error bars indicate standard
error.

(***) p-value < 0.001, Student’s t-test. (B) Viability analysis of vector control or cells

overexpressing PLTP treated with 10 µM Nutlin and indicated doses of RSL3 for 72 hours.
Viability normalized to treatment with 10 µM Nutlin alone. Data are representative of three
independent experiments, four technical replicates, error bars represent standard error of mean.
(C) Viability analysis of vector control or cells overexpressing PLTP treated with 10 µM Nutlin and
0.1 µM RSL3 for 72 hours (single point from b). Error bars indicate standard deviation, (***) pvalue < 0.001. (D) Lipid peroxidation in cells overexpressing PLTP treated with 0.5 µM RSL3 for 3
hours was assessed by flow cytometry using C11-BODIPY. Data are representative of three
independent experiments. (E) Quantification of lipid peroxidation levels. Error bars indicate
standard deviation. n=3, (**) p-value < 0.01

3.3.4 PLTP silencing does not impact other cell death processes
To verify that the cell death being observed is, in fact, due to ferroptosis, a
rescue assay was performed using ferroptosis-specific rescue agents ferrostatin and
liproxstatin. PLTP-silenced cells experienced 100% cell death when treated with a high
dose of RSL3. However, when PLTP-silenced cells were pretreated with either
ferrostatin or liproxstatin for 30 minutes, and then treated with the same dose of RSL3,
little to no cell death was observed indicating that ferroptosis is the primary mode of cell
death occurring in these PLTP-silenced cells (Figure 3.5A). Prior studies from our lab
show that the S47 variant is impaired for cell death by cisplatin (Jennis et al., 2016). No
significant differences in cell death were observed in PLTP-silenced cells when treated
85

with cisplatin (Figure 3.5B-C). We next assessed several other chemotherapeutic agents
such as doxorubicin, etoposide, camptothecin and tunicamycin. Our studies revealed no
significant differences in cell viability when comparing PLTP-silenced cell lines to the
shCtrl cell lines (Figure 3.5D-G), highlighting the fact that PLTP silencing seems to affect
ferroptosis but not other cell death pathways.

Figure 3.5: PLTP silencing does not affect sensitivity to other forms of cell death.
(A) Viability analysis of PLTP knockdown cells subjected to indicated treatments. Cells pretreated
with either 2 µM ferrostatin or 50 nM liproxstatin for 30 minutes, followed by treatment with 1 µM
RSL3 for 24 hours. Viability normalized to untreated cells, error bars indicate standard deviation,
n = 4. (B) Viability analysis of short hairpin control or PLTP knockdown cells treated with indicated
doses of cisplatin for 72 hours. Error bars represent standard error of mean, n = 4. (C) Viability
analysis of short hairpin control or PLTP knockdown cells treated 1 µM cisplatin for 72 hours
(single point from b). Error bars indicate standard deviation, p-value not significant. (D-G) Viability
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analysis of short hairpin control or PLTP knockdown cells treated with indicated doses of (d)
doxorubicin, (e) etoposide, (f) camptothecin or (g) tunicamycin for 72 hours. Error bars represent
standard error of mean, n = 4. No significant differences observed.

3.3.5 PLTP protects cells from ferroptotic cell death by promoting lipid storage
We next sought to determine the mechanism by which PLTP mediates
ferroptosis resistance. It is well known that PLTP plays a role in transporting various lipid
molecules, including phosphatidylethanolamine which is one of the key lipids that
undergo peroxidation at the cellular membrane during ferroptosis (Albers et al., 2012;
Kagan et al., 2017). A recent study demonstrated enhanced lipid storage in the form of
lipid droplets can inhibit ferroptosis (Bai et al., 2019). This is supported by other studies
that show lipid droplet formation can protect cells from forms of oxidative cell death by
sequestering polyunsaturated fatty acids away from the cellular membrane (Li et al.,
2018). Based on these findings, we hypothesized that PLTP could promote ferroptosis
resistance by transporting lipids away from the cellular membrane and into lipid droplets,
thereby reducing the lipids available to undergo peroxidation at the membrane.
We verified PLTP influences lipid droplet formation by visualizing cells stained
with the lipid droplet marker BODIPY 493/503 and found PLTP-silenced cells showed
very few lipid droplets in comparison to the control (Figure 3.6A). To determine whether
PLTP drives ferroptosis resistance through enhanced lipid storage, we treated cells
overexpressing PLTP with RSL3 and assessed the levels of lipid droplets using flow
cytometry. When comparing control cells to cells overexpressing PLTP that are
untreated, there is an increase in lipid droplet content as depicted by the rightward shift
of the solid green curve to the solid orange curve (Figure 3.6B). Upon treatment with
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RSL3, there is a decrease in lipid droplet content in both control cells and cells
overexpressing PLTP, as shown by the leftward shift of the curves from the solid colors
to the respective transparent colors (Figure 3.6B). These data are consistent with
previously reported data showing induction of ferroptosis leads to a decrease in lipid
droplet levels (Bai et al., 2019). Whereas RSL3 causes decreased lipid droplet
accumulation in cells overexpressing PLTP, the overall lipid droplet levels remain higher
compared to the control cells. (Figure 3.6B). Taken together, these data support the
premise that PLTP protects cells from ferroptotic cell death by enhancing lipid storage
and preventing lipids from undergoing peroxidation at the cellular membrane (Figure
3.6C).
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Figure 3.6: A model for PLTP in ferroptosis resistance by promoting lipid storage.
(A) Knockdown of PLTP decreases lipid droplet accumulation, visualized using BODIPY 493/503.
DAPI staining used to visualize nuclei, scale bar represents 20 μm. (B) Lipid droplet accumulation
assessed using BODIPY 493/503 in cells overexpressing PLTP, treated with and without 500 nM
RSL3 for 12 hours. Data representative of 2 independent experiments, 4 technical replicates. (C)
Proposed mechanism of how PLTP promotes ferroptosis resistance: PLTP enables increased
lipid droplet formation, thus protecting polyunsaturated fatty acids from undergoing ferroptosis at
the cell membrane.
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3.4 Discussion

Programmed cell death is a complex network that is mediated by various intrinsic
and extrinsic signals. In recent years lipids have emerged as key drivers of various cell
death pathways, shown to play roles in apoptosis, necroptosis and ferroptosis
(Magtanong et al., 2016). Cell death via ferroptosis occurs by lipid peroxidation at the
cellular membrane, yet precise mechanisms of this process are still being ironed out
especially with regard to the role of p53 (Gnanapradeepan et al., 2018; Murphy, 2016).
In this study, we demonstrate that the p53 target gene PLTP promotes ferroptosis
resistance in HepG2 cells. Silencing PLTP was found to sensitize cells to cell death by
RSL3 and increased lipid peroxidation, while overexpressing PLTP led to greater
resistance to cell death by RSL3 and decreased lipid peroxidation. The cell death
differences that were observed were confirmed to be specific to ferroptosis. PLTP
appears to increase lipid storage in the form of lipid droplets, thereby protecting lipids
from peroxidation at the membrane. These data are the first to characterize the function
of PLTP in a p53 dependent context and reveal a novel potential role for p53 in driving
ferroptosis resistance through lipid transport.
There are several experiments that should be done in order to strengthen these
findings. An important control for the short hairpin silencing data is to combine treatment
with a non-silenceable, rescue cDNA. This study was performed in HepG2 cells, and
further work in other liver cancer cell lines containing WT p53 such as SK-Hep-1 are
required. It would also be interesting to see if this phenotype is specific to liver cancer
cells, thus extending these studies to other lipid rich cancer cell lines such as melanoma
or ovarian cancer would be very interesting. We provided evidence that PLTP increases
lipid storage, yet the exact lipids that are involved remain unknown. Ferroptosis is driven
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through oxidation of phophatidylethanolamines containing arachidonic acid or adrenic
acid (Kagan et al., 2017) and it is known that certain lipid types, such as
monounsaturated fatty acids, can lead to ferroptosis resistance (Magtanong et al., 2019).
A lipidomics study would be very informative to further dissect this mechanism and
understand exactly what lipid types are involved in PLTP-mediated transport that results
in ferroptosis resistance. PLTP is known to transport Vitamin E (also known as atocopherol), a lipophilic antioxidant that has been shown to protect cells from oxidative
damage and ferroptosis.(Raederstorff et al., 2015; Yang and Stockwell, 2016). An
alternate hypothesis is that PLTP drives ferroptosis resistance by transporting Vitamin E
to cells, thus it would be worthwhile to investigate the role of Vitamin E in this process.
Insight into the function of PLTP come from studies of the PLTP knockout
mouse. The PLTP knockout mouse displays an interesting and complex phenotype.
These mice lose the ability to transfer lipids such as phosphatidylcholine,
phosphatidylethanolamine, phosphatidylinositol, and sphingomyelin, as well as partially
losing the ability to transfer free cholesterol (Jiang et al., 1999). These data demonstrate
the in vivo relevance of PLTP and highlights the crucial role PLTP plays in mediating the
transfer of lipids implicated in ferroptosis. PLTP knockout mice were also found to have
significantly lower levels of HDL cholesterol found in the plasma, due to impaired
cholesterol absorption in the intestine (Liu et al., 2007). It was also found that HDL from
PLTP deficient mice had improved anti-inflammatory properties and that these mice
have decreased atherosclerosis (Yan et al., 2004). PLTP has been shown to regulate
the phagocytic activity of macrophages and microglial cells. PLTP deficient mice express
much lower levels of cytokine interleukin 6 (IL-6) and lower levels of infiltrating
macrophages after stress (Desrumaux and Lagrost, 2018). Studies in humans show
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increased PLTP activity in patients with bacterial infection and systemic inflammation,
supporting the role of PLTP in immune function (Desrumaux et al., 2016). These
combined studies suggest PLTP plays a complex role in mediating several processes
ranging from lipid metabolism to immune function, and this could account for why PLTP
has altered regulation in the S47 mouse.
The S47 variant is impaired for ferroptosis and tumor suppression. Hence, we
predicted that a gene such as PLTP, which shows impaired induction in S47 cells, might
confer ferroptosis sensitivity. In contrast we found that this gene mediates ferroptosis
resistance. Indeed, our data suggest that even p53 confers ferroptosis resistance in
HepG2 cells, and not sensitivity as one might have been predicted. These findings
reinforce the premise that the role for p53 and its target genes in ferroptosis sensitivity is
complex and may be cell type or tissue specific. Our findings add to the growing body of
literature on the complex role of p53 in regulating ferroptosis. One point to consider is
whether stabilization of p53 is a critical step in mediating ferroptosis resistance. Many of
our experiments used Nutlin to activate p53, and prior studies found the most
pronounced effects on ferroptosis resistance occur after a 24-hour stabilization of p53
with Nutlin (Tarangelo et al., 2018). It is also necessary to consider the type of stress
encountered and location of stress that triggers the p53 response, as it is well known
that p53 responds differently under different circumstances (Kastenhuber and Lowe,
2017). Our data on the effect of low nutrient media increasing ferroptosis sensitivity in a
p53 dependent manner highlights the fact that metabolites play a key role in determining
sensitivity to ferroptosis, consistent with prior findings (Tarangelo et al., 2018). The
crosstalk between various pathways is also very important to bear in mind. A recent
study provided evidence that MDM2 and MDMX, known negative regulators of p53,
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promote ferroptosis through PPARα-mediated lipid remodeling. Thus, it is important to
consider the intricate nature of metabolic regulation and context specificity when thinking
about both p53 and ferroptosis.
The role of p53 is not limited to tumor suppression, as p53 has been shown to
possess anti-atherogenic properties (Mercer and Bennett, 2006; Tabas, 2001). PLTP
has been extensively characterized in the context of atherosclerosis and studies have
shown that low levels of PLTP are associated with greater risk of atherosclerosis
(Schgoer et al., 2008). There is evidence that inhibition of ferroptosis alleviates
atherosclerosis (Bai et al., 2020), therefore a possible explanation could be that p53
functions to prevent atherosclerosis by inducing ferroptosis resistance through PLTP.
Taken together, our findings provide evidence for a novel role for p53 and a p53 target
gene on the regulation of ferroptosis through lipid transport. More studies of the role of
p53 and PLTP in ferroptosis sensitivity in the liver and other tissues of the WT and S47
mouse can help clarify these roles.

3.5 Materials and Methods
3.5.1 RNA Sequencing
WT and S47 LCLs were treated with 5 µM Nutlin for 30 minutes followed by the addition
of 25 µM TBH for 0, 8 and 24 hours. RNA was extracted using RNeasy minikits (Qiagen)
following the manufacturer’s protocol. The QuantSeq FWD library preparation kit
(Lexogen) was used to generate 3’ mRNA-seq libraries from DNase I-treated RNA. The
Agilent Tapestation and Agilent DNA 5000 Screentape were used to determine overall
library size and real-time PCR (Kapa Biosystems) was used to quantitate the libraries.
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Libraries were pooled and the NextSeq 500 (Illumina) was used to carry out high-out-put
single-read

75-base-pair

next-generation

sequencing.

Bowtie2

(Langmead

and

Salzberg, 2012) was used to align RNA-seq data against the human genome version
hg38. Raw read counts for each gene were estimated using RSEM version 1.2.12
software (Li and Dewey, 2011). The significance of differential expression between
samples was determined using DESeq2 (Love et al., 2014).

3.5.2 qRT-PCR
RNA was extracted from cells using the RNeasy minikits (Qiagen) following the
manufacturer’s protocol. Equal amounts of the isolated RNA were used to generate
cDNA using a high-capacity reverse transcription kit (Applied Biosciences, 4368814).The
Brilliant III UltraFast SYBR Green qPCR mix kits (Agilent) were used to conduct qPCR
on the Stratagene Mx3005P machine (Agilent). RNA expression levels were normalized
to housekeeping gene 18S for human and cyclophilin A for mouse. Primer sequences
are as follows: PLTP (human-F) 5’-TGATTGACTCCCCATTGAAGC-3’ and (human-R)
5’-CGTCCATAGTCATGCTGGACA-3’.

Pltp

TTCCTCCTCAACCAGCAGATCT-3’

and

(mouse-F)

5’-

(mouse-R)

5’-

CAGGAGGGAGTTGAGCAACAC-3’.

3.5.3 Silencing and overexpression studies
PLTP knockdown cell lines were generated by lentiviral infection, using the vector
pLKO.1-puro-carrying

shRNA

sequence

[CTGATGCTTCAAATCACCAAT;

against

human

TRCN0000150129],
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PLTP

(shRNA1
shRNA2

[CGAATCTATTCCAACCATTCT;

TRCN0000148250])

and

human

TP53

(TCAGACCTATGGAAACTACTT, TRCN0000003754). Short hairpin constructs and
packaging vectors were cotransfected in 293-FT cells to generate lentivirus. HepG2 cells
were infected with lentivirus with 8 µg/mL polybrene, spun for 30 minutes at 2250 rpm,
allowed to rest for 3.5 hours followed by a media change. Puromycin was added the
following day at 2 µg/mL and gene knockdown was validated by qRT-PCR. Cells
overexpressing PLTP were generated by transfecting the vector pcDNA3.1+/C-(K)DYK
with and without PLTP ORF (NM_006227.3) obtained from GenScript. Transfections
were performed with Lipofectamine 3000 (ThermoFisher) following the manufacturer’s
protocol.

3.5.4 Flow cytometry
Analysis of lipid peroxidation was performed using C11-BODIPY 581/591 (ThermoFisher
D3861) and analysis of lipid droplet accumulation was performed using BODIPY
493/503 (ThermoFisher D3922). Cells were plated at a density of 3x105 cells per well in
6-well plates. The following day, cells were treated with 0.5 µM of RSL3 for 3 hours.
Cells were collected, washed with PBS and stained with 5 µM of C11-Bodipy for 30
minutes at 37°C for lipid peroxidation analysis or 2 µM of Bodipy 493/503 for 15 minutes
at 37°C for lipid droplet analysis. Cells were then washed with PBS three times and
analyzed using FACSCelesta (Becton Dickinson) flow cytometer. Dead cells were
removed from analysis using FSC/SSC profiles, and cell doublets were eliminated by
comparing forward scatter signal height vs forward scatter signal area. At least 10,000
events in the analysis gate were obtained.
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3.5.5 Immunofluorescence staining
Cells were washed once with PBS, fixed in 4% PFA for 10 minutes, followed by 3 PBS
washes. Samples were then treated with 2 µM of Bodipy 493/503 (ThermoFisher D3922)
for 15 minutes at 37°C in the dark. The cells were mounted with media containing DAPI
and images were captured using the Leica TSC SP5 microscope.

3.5.6 Immunohistochemistry
Liver tissues were fixed in formalin overnight at 4°C. The following day, tissues were
washed in 1X PBS and placed in 70% ethanol. The tissue embedding and sectioning
were performed by the Wistar Institute Histotechnology Facility. Paraffin embedded
sections were de-paraffinized in xylene (Fisher, X5-SK4), re-hydrated in ethanol (100%95%-85%-75%) and then placed in distilled water. Sample slides were steamed in 10
mM Citrate Buffer, pH 6, for antigen retrieval. Three percent hydrogen peroxide was
used to quench endogenous peroxidase activity and slides were blocked for 1 hour
(Vector Laboratories, S-2012). The slides were incubated with the primary antibody
PLTP (1:100, Santa Cruz sc-271596) overnight at 4°C.

The next day, slides were

washed with PBS, incubated with HRP-conjugated secondary antibody for 30 minutes
and treated with DAB chromogen (D5637). Hematoxylin was used to perform a light
counterstaining. The Nikon 80i upright microscope was used to image slides, at least
four fields per section were imaged.

3.5.7 Viability assays
Cells were seeded at 2000 cells per well on a 96-well plate and were grown overnight at
37°C. The following day cells were treated with the following drugs at indicated
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concentrations for 72 hours for IC50 assays: erastin (Cayman Chemicals), RSL3 (Apex
Bio), tert-Butyl hydroperoxide/TBH(Sigma), Nutlin (Calbiochem), cisplatin (Acros
Organics), Etoposide (Sigma), Camptothecin (Cayman Chemicals), Doxorubicin (Cell
Signaling). For rescue assays, cells were pretreated with ferrostatin (Cayman
Chemicals) or liproxstatin (Sigma) for 30 minutes prior to treatment with RSL3 for 24
hours. At assay endpoint, cells were treated with Alamar blue (Life Technologies
Dal1025) for 3 hours at 37°C and absorbance was read out using a SynergyHT plate
reader (BioTek). GraphPad Prism software was used to perform the data analysis.

3.5.8 Mammalian Cell Culture
Human WT LCLs (Catalog ID GM18870) and S47 LCLs (Catalog ID GM18871) were
obtained from the Coriell Institute (Camden, New Jersey) and grown in RPMI (Corning
Cellgro) supplemented with 15% heat inactivated fetal bovine serum (HyClone, GE
Healthcare Life Sciences) and 1% penicillin/streptomycin (Corning Cellgro). WT and S47
MEFs were generated as previously described (Jennis et al., 2016) and maintained in
complete growth medium. HepG2 cells were obtained from ATCC (ATCC HB-8065) and
maintained in complete growth medium. Complete growth medium is composed of
DMEM (Corning Cellgro, 4.5 g/L glucose) supplemented with 10% fetal bovine serum
(HyClone, GE Healthcare Life Sciences) and 1% penicillin/streptomycin (Corning
Cellgro). Cells were grown in a 5% CO2 humidified incubator at 37°C. For low glucose
low serum experiments, cells were grown in DMEM containing 1 g/L (Gibco 11885084)
and 1% fetal bovine serum.
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3.5.9 Western blot
Protein lysates were obtained from indicated cell lines and 50-100 µg of protein was run
on SDS-PAGE gels using 10% NuPAGE Bis-Tris precast gels (Life Technologies).
Proteins were transferred onto polyvinylidene difluoride membranes (IPVH00010, pore
size: 0.45 mm; Millipore Sigma) and blocked for 1 hour in 5% milk. Primary antibodies
include PLTP 1:1000 (Abcam ab18990) and GAPDH 1:10,000 (14C10, Cell Signaling,
2118). HRP-conjugated rabbit secondary antibody (Jackson Immunochemicals) was
used at a 1:10,000 dilution. Blots were treated for 5 minutes with ECL (Amersham,
RPN2232) and autoradiography was used to determine protein levels.

3.5.10 Statistical Analysis
All experiments were performed in triplicate unless otherwise stated and the two-tailed
unpaired Student t-test was performed to determine significance. All in vitro data are
reported as the mean ± SD unless stated otherwise. Statistical analyses were performed
using GraphPad Prism, p-values are as follows: (*) p-value < 0.05, (**) p-value < 0.01,
(***) p-value < 0.001, (****) p-value < 0.0001.
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Chapter 4: Future Direction and Concluding Remarks

4.1 Summary of findings

For decades it was believed that p53 functions as a tumor suppressor predominantly by
controlling apoptosis, senescence and cell cycle arrest. However, in recent years more
data has begun to emerge highlighting the key role p53 plays in less studied processes
such as metabolism and ferroptosis. This is a rapidly expanding field and much more
work remains to be done to fully understand how exactly p53 behaves in various
contexts. Coding region variants of p53 can be used as tools to further dissect such
mechanisms and enable us to develop a broader understanding of how p53 functions.
This thesis provides deeper insight on how the S47 SNP of TP53 regulates metabolism
and ferroptosis.

In our first study, we sought to characterize the metabolic phenotype that we had
observed in the S47 mouse. I was able to demonstrate the following:

1. S47 cells and tissues exhibit increased mTOR activity compared to the WT
counterpart, as determined by assessing levels of mTOR markers using Western
blot and immunohistochemistry.
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2. S47 cells show higher rates of cellular metabolism, as demonstrated through
Seahorse assays assessing cellular respiration and glycolysis, as well as
analysis of metabolites using the YSI analyzer.

3. The increased mTOR activity in S47 cells can be attributed to greater interaction
between mTOR and Rheb, resulting from a decreased interaction between
GAPDH and Rheb. This was validated by performing both proximity ligation
assays and co-immunoprecipitation assays.

4. The altered mTOR-Rheb binding observed in S47 ultimately stems from the
altered redox state present in S47 cells. The conformation of GAPDH is altered in
S47 cells due to elevated glutathione levels, thus impairing the GAPDH-Rheb
interaction. We were able to show that manipulating levels of glutathione could
alter the GAPDH-Rheb interaction.

5. S47 mice possess greater metabolic efficiency compared to WT mice. In both
comprehensive lab animal monitoring studies and treadmill studies, S47 mice
demonstrated greater metabolic resilience.

Taken together, this study shows how a single amino acid change in p53 can lead to
a profound change in various metabolic processes. Our work elegantly connects the
mTOR pathway, p53 and the role of redox state together, and provides a unique lens to
think about the interplay between these various pathways.
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We next sought to use the S47 variant as a tool to unearth novel p53 target
genes that could play a role in mediating ferroptosis. In our second study, I identified
PLTP as a p53 target gene that appears to mediate ferroptosis resistance and
demonstrated the following:

1. PLTP is expressed at much lower levels in S47 compared to WT. I validated this
through multiple methods assessing expression on the mRNA, protein and tissue
level.

2.

p53 regulates the expression of PLTP in HepG2 cells. By generating a p53 null
cell line, I was able to validate that PLTP is expressed in a p53 dependent
manner.

3. PLTP promotes ferroptosis resistance. After silencing PLTP, I found increased
sensitivity to RSL3-induced cell death and increased levels of lipid peroxidation.
Consistent with this finding, overexpressing PLTP led to decreased sensitivity to
RSL-induced cell death and decreased levels of lipid peroxidation.
4. The RSL3-induced cell death that is observed is ferroptosis specific. This was
validated by using ferroptosis specific rescue agents, as well as observing no
significant

differences

in

viability

after

treatment

with

many

other

chemotherapeutic agents.
5. PLTP protects cells from ferroptosis by enhancing lipid storage. We found that
PLTP contributed to increased levels of lipid droplets and also had overall
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increased levels of lipid droplets after treatment with RSL3. This suggests that
PLTP is sequestering lipids away from the cell membrane, leaving less lipids
available to undergo peroxidation.

This study identifies PLTP as a novel p53 target gene that plays a role in regulating
ferroptosis and adds to the growing body of literature on the perplexing role of p53 in
ferroptosis. The exact role of p53 in mediating ferroptosis remains inconclusive, as it
promotes ferroptosis in certain situations and prevents ferroptosis in other situations.
However, what is clear from both studies presented in this dissertation is that the
function of p53 appears to be very context specific. Several factors such as type of
stress, duration of stress, location of the stress, and other parameters all contribute to
the response p53 elicits.

4.2 Outstanding questions regarding p53, S47, mTOR, ferroptosis and tumor
suppression

There are many remaining questions with regard to the S47 variant. One major
point of future investigation regards the impact of this genetic variant on glucose
metabolism. A difference that was observed but not further pursued is that the GLUT
family of glucose transporters are expressed at much lower levels in S47 compared to
WT. It is known that p53 downregulates the expression of GLUT1 and GLUT4
(Schwartzenberg-Bar-Yoseph et al., 2004), which would result in less available glucose
in a cancer cell that could be used for other anabolic processes. Our data suggest S47
cells consume more glucose, yet we have observed that various members of the GLUT
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family, including GLUT 1, GLUT3, GLUT4 and GLUT5, are expressed at much lower
levels in S47 tissues compared to WT. This raises the question, how exactly are S47
cells importing this excess glucose? It suggests that the S47 cells are likely utilizing
other pathways to modulate glucose uptake and usage. Moreover, one might have
hypothesized that increased glucose consumption would result in larger cells or
increased rates of proliferation in S47. However, we have not observed any changes in
proliferation rate or cell size in S47 MEFs or lymphoblastoid cells, compared to WT, in
vitro. That being said, we have noted increased Ki-67 staining in tumors containing the
S47 variant, compared to WT (Barnoud et al., 2018). Additionally, Ki-67 staining in small
intestine and skeletal tissue appears to be increased in S47 mouse tissues (K.
Gnanapradeepan, unpublished results). It is also worthwhile to note that the ferroptotic
defect in S47 contributes to iron accumulation in macrophages and the spleen, however
no major differences are observed in tissues such as the liver. These data reinforce our
findings that the phenotype of the S47 variant appears to be restricted to certain tissues.
Another unresolved question is the basis for the tissue-restricted increase in
mTOR activity that we observed in S47 tissues, in spite of the fact that we found
evidence for increased levels of reduced glutathione in multiple tissues of the S47
mouse. For example, we were unable to detect significant changes in levels of mTOR
markers when comparing S47 liver to WT liver, however S47 liver does exhibit higher
levels of glutathione (Leu et al., 2019). These data suggest that there are other
pathways that are likely contributing to the increased mTOR phenotype aside from the
mTOR-Rheb-GAPDH interaction that we described, and more work remains to be done
in this area.
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We have identified the regulation of glutathione synthesis, and the consequent
regulation of cellular redox state, on the regulation of mTOR. Two obvious avenues
stem from this area.

The first involves the potential for redox regulation of other

enzymes in metabolism. Indeed, our collaborators have identified at least two other key
metabolic enzymes, PKM2 and G6PDH, as redox sensitive proteins that also show
altered regulation in S47 cells (Leu et al., 2020). It is likely that there are several other
redox sensitive proteins impacted in S47 cells, thereby affecting several other processes
beyond what is normally regulated by p53.
A second area for future analysis is the potential contribution of enhanced mTOR
activity to the increased cancer risk, and resistance to ferroptosis in S47 mice and
humans. Whereas the contribution of increased mTOR activity to cancer risk in S47
humans remains to be determined, there are data supporting increased mTOR activity in
ferroptosis resistance. For example, Yi et al. found that oncogenic activation of the
PI3K-AKT-mTORC1 signaling axis causes ferroptosis resistance (Yi et al., 2020). The
authors found that cancer cells containing mutations in the PI3K-AKT-mTORC1 pathway
were far more resistant to cell death by RSL3. Interestingly, these cells were sensitized
to cell death by RSL3 when treated concurrently with mTOR inhibitors such as
Temsirolimus and Torin1. The authors went on to show that this ultimately stems from
mTORC1 activating the master regulator of lipid metabolism, SREBP1, which then goes
on to upregulate the expression of SCD1, a gene implicated in mediating ferroptosis
resistance. Pharmacological and genetic inhibition of both SREBP1 and SCD1 resulted
in increasing ferroptosis sensitivity in cancer cells harboring the PI3K-AKT-mTOR
mutation. The authors demonstrated how the synergistic effects of combining ferroptotic
induction with mTOR inhibition can significantly reduce tumor formation in vivo (Yi et al.,
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2020). This study highlights how inducing ferroptosis can serve as a promising
therapeutic approach for cancers that possess specific genetic backgrounds.
This study connects lipid metabolism to the mTOR/ferroptosis phenotype and
highlights how these pathways appear to be intricately connected. The data presented
corroborate a previous study that also demonstrated elevated mTOR activity suppresses
ferroptosis in cardiomyocytes (Baba et al., 2018). Knowing that S47 exhibits elevated
mTORC1 activity, impaired ferroptosis and altered expression of lipid metabolism genes,
it would be worthwhile to explore if and how these various pathways are interconnected.
For example, it would be interesting to determine if the elevated mTOR activity observed
in S47 is directly responsible for the ferroptosis defect. To assess this, one could first
treat S47 cells with mTOR inhibitors such as Temsirolimus or Torin1, and then
determine if ferroptosis sensitivity is affected in S47 cells. If this looks promising, the
next logical step would be to assess the impact off this combined therapy in vivo. A key
experiment would be to treat S47 mice with a ferroptosis inducer such as imidazole
ketone erastin (IKE), and with an mTOR inhibitor such as Temsirolimus or Torin1 and
see if this combined therapy significantly reduces tumor formation.
There is also therapeutic potential for combined therapy with mTORC1 inhibitors
and inhibitors of glutathione. A study published by Li et al. demonstrated that combining
inhibitors of mTORC1 and glutamate cysteine ligase (GCLC), the rate limiting enzyme in
glutathione synthesis, can enhance cell death in cells with high mTORC1 activity. The
authors created mTORC1 driven tumor cells by generating mouse embryonic fibroblasts
null for Tsc2, a negative regulator of the mTOR pathway. When mTORC1 is hyperactive,
the authors found increased levels of antioxidants such as NADPH and glutathione.
Interestingly, the authors discovered treating cells with rapamycin decreases overall
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glutathione content in addition to decreasing mTOR activity. In vivo, it was found that
using nontoxic doses of BSO, an inhibitor of GSH synthesis, with rapamycin promotes
significant tumor regression in Tsc2-deficient xenograft models (Li et al., 2016). As
described in Chapter 2, the S47 variant has higher mTOR activity and higher glutathione
levels, thus it would be worthwhile to treat S47 mice with an inhibitor of glutathione such
as BSO or DEM in conjunction with rapamycin.
In conclusion, there are several opportunities for further exploration harnessing
the mTOR, ferroptosis, metabolism and redox phenotype observed in the S47 variant.
The following experiments are ways to exploit the unique differences observed in the
S47 variant, and determine if manipulating these factors can reduce cancer risk in vivo:

1. Treat S47 mice with reagents that deplete glutathione levels such as DEM and
BSO.
2. Treat S47 mice with mTOR inhibitors such as rapamycin, Temsirolimus and
Torin1.
3. Treat S47 mice with a combination of the aforementioned mTOR inhibitors and
glutathione inhibitors, such as BSO.
4. Treat S47 mice with a combination of the aforementioned mTOR inhibitors and
ferroptosis inducers, such as imidazole ketone erastin.

The ultimate goal of studying the S47 variant is to develop better therapeutic options for
patients who carry this allele. To that end, our lab has identified cisplatin and BET
inhibitors as two classes of drugs that have superior efficacy on S47 tumors compared to
106

WT tumors (Barnoud et al., 2018). S47 tumor cells have also shown preferential
sensitivity to the glycolytic poison 2-deoxy-glucose (Barnoud et al., 2019). Much of the
data presented and discussed are taken from cells and mouse experiments, thus it is of
utmost importance to gather more genetic data from human studies with patients
carrying this S47 variant. Doing so will enable a better understanding of the phenotype
and provide opportunity for improved personalized medicine approaches.
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